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ABSTRACT AND KEYWORDS
Title: Evaluating the utility of S100A7 in identifying oral dysplastic lesions that will
progress to oral squamous cell carcinoma
Introduction: Recently, S100A7 has been shown to be a potentially useful marker for
identifying oral lesions at risk of transformation from dysplasia to squamous cell
carcinoma. Our hypothesis is that high S100A7 protein expression predicts the
transformation of oral epithelial dysplasia to malignancy. The objective of our study is to
semi-quantitatively evaluate the level of S100A7 expression in dysplastic lesions which
have transformed into oral squamous cell carcinoma using immunohistochemistry, and
correlate these results with other methods of analysis including the standard 3-tier
histopathological diagnosis, the 2-tier histopathological diagnosis, and S100A7
evaluation utilizing Straticyte™, a digital proprietary technique designed to communicate
S100A7 expression in dysplastic tissue as a 5-year risk of malignant transformation. In
addition, a pilot study evaluating the utility of QuPath, an open source software for
bioimage analysis, will be assessed to determine if it more reliably correlates with the
known outcomes of the sample populations. MAPK pathway proteins ERK1/2, p38, and
JNK, will also be assessed for dysregulated phosphorylation in each of the sample
populations.
Methods: Formalin fixed paraffin embedded specimens from 48 patients with oral
squamous cell carcinoma, where from the same site, a non-cancerous biopsy had been
previously obtained, were included in the study. Thirty five (35) patients with multiple
biopsies of dysplasia which had not advanced to squamous cell carcinoma, and 25
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patients with a diagnosis of hyperkeratosis were included as control groups. In addition to
the 3-tier dysplasia diagnoses of mild, moderate and severe, 2-tier diagnoses of low grade
or high grade were assigned to each of the tissue samples. Specimens were stained for
S100A7 protein using a standard immunohistochemistry protocol. Expression of S100A7
was assessed semi-quantitatively, using an intensity and proportion scale, as well as by
image analysis using Straticyte™ and QuPath. As S100A7 is associated with activation
of the MAPK signaling pathway activity, phosphorylated proteins ERK1/2, p38, and JNK
were also evaluated via immunohistochemistry.
Results: Manual scoring of S100A7 staining of epithelium in the three study populations
was carried out and compared to the 3-tier and 2-tier grading schemes, Straticyte™, and
QuPath. Manual scoring had strong correlational relationships with QuPath and Straticyte
based on Pearson correlation coefficients, and allowed differentiation of dysplastic from
the Control groups. Straticyte™, a test which utilizes a proprietary algorithm for the
epithelial S100A7 stain assessment, allowed differentiation, of dysplastic tissue samples
that progressed to OSCC, from those that did not (p < 0.05).
Conclusion: S100A7 holds potential for assisting in the identification of patients with
dysplastic oral premalignant lesions that have an increased risk of malignant
transformation as compared to those who do not.

Key Words: S100A7, Oral Squamous Cell Carcinoma, Oral Dysplasia, MitogenActivated Protein Kinase, Pathology, immunohistochemistry, QuPath, Straticyte™
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SUMMARY FOR LAY AUDIENCE
Despite increased awareness for the risk factors of oral cancer, there continues to be an
increase in the number of cases globally and in Canada. Unfortunately, the prognosis is
still grim and mortality also continues to rise. It is typical for cancerous lesions within
the oral cavity to arise from pre-existing lesions, which as a group are called potentially
malignant oral lesions. Therefore, in an attempt to identify and treat these lesions early,
biopsies are conducted by health care practitioners and the tissue is viewed with
microscopy to identify lesions that are potentially cancerous before they become invasive
and spread to other parts of the body. However, it can be difficult to identify which of
these lesions will progress to cancer, especially early. In this study we looked at a protein
that is found within cells of the mucosa, called S100A7, to see if we could identify a
change in its expression in lesions that progress to cancer as compared to those that do
not. We looked at tissue from patient biopsies from three categories: Those that
eventually developed cancer, those that did not, and those that had lesions that
demonstrated relatively normal tissue. We looked to see if there were differences in
S100A7 between these groups. Our evaluation consisted of a manual score, in which we
evaluated the tissue samples under the microscope and scored the S100A7 expression, a
commercially available digital scoring method called Straticyte™ in which a proprietary
algorithm is used to evaluate and score S100A7 expression to determine a 5-year risk of
progression to cancer, and a pilot study to see if an open-source bioimage analysis
software, QuPath™ had utility in evaluating the tissue consistently as well. We looked to
see if any method more reliably identified lesions likely to progress to cancer as
compared to the conventional 3-tier and 2-tier methods of diagnosing tissue dysplasia.
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CHAPTER 1: LITERATURE REVIEW
1.1 Oral squamous cell carcinoma
1.1.1 Epidemiology
Oral squamous cell carcinoma (OSCC) is a clinically significant malignant lesion
affecting many people worldwide as it remains a significant cause of morbidity and
mortality. Management of the malignancy is dependent upon both local and distant
spread, therefore, early identification of tissue that is at risk of transforming into
squamous cell carcinoma is thought to be essential in reducing harm to patients.
According to 2020 data from the World Health Organization, Oral and lip cancer
accounts for 377 713 new cases this year, and 177 757 deaths, which is a slight increase
from 2012 data, when approximately 300 400 new cases of oral squamous cell carcinoma
occurred, with 145 400 deaths that year (1)(2). The total incidence is highest in Southcentral Asia with 174 448 cases, and the greatest cumulative risk is in Melanesia (Fiji,
France, New Caledonia, Papua New Guinea, Solomon Islands, Vanuatu). The greatest
total incidence is among men with 264 211 cases as compared to women with 113 502.
With respect to mortality, the greatest total number is again in South-central Asia with 98
015 with the highest cumulative risk in Melanesia at 0.82. Men had the highest death rate
with a total of 125 022 deaths, while woman accounted for 52 735 deaths. North America
sees 27 469 new cases annually, with total mortality of 4985(1). As the burden continues
to be high, the diagnosis and management of oral potentially malignant lesions remains
an important issue within healthcare, and methods leading to improved outcomes still
stands to have significant benefit for a large population. As many oral squamous cell
carcinomas arise from pre-existing lesions, biopsy and management of these lesions has
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played a large role in our attempts to reduce the risk of OSCC (3). Of all head and neck
cancers, 90% are squamous cell carcinoma (4).
Head and neck cancers originate in one of the oral cavity, oropharynx, nasopharynx,
hypopharynx, and larynx. While anatomically close, the oral cavity and oropharynx are
separate entities. The oral cavity can be divided anatomically into specific zones, some
of which are at increased risk of malignant transformation relative to others, such as the
ventrolateral tongue, and floor of mouth, which are at greater risk than the dorsal tongue
and hard palate (5). This may be attributed not only to the settling of carcinogenic agents
within these areas, but also due to the rapid rate of turn over that was found in the floor of
mouth and ventral tongue relative to the dorsal tongue and hard palate. In addition, the
tonsillar pillars and soft palate are also high risk sites (5).
1.1.2 Risk factors
Tobacco use and alcohol consumption are the greatest risk factors for OSCC. In a large
pooled analysis consortium regarding the effects of tobacco use and alcohol consumption
from 2009, it was noted that 72% of all head and neck cancers were related to the use of
either or both of these. The combined use resulted in a synergistic effect, and the risk of
carcinogenesis was greater than either entity when used alone (6). Smoking imparts the
greatest risk to the upper aerodigestive tract, but smokeless tobacco is also an important
risk factor. Cessation of these habits has been shown to be beneficial, reducing the risk of
malignancy very close to the level of never smokers after approximately 10 years (7). In
addition to tobacco, Betel quid chewing, which is common practice in Asia, also
increases the risk of oral and oropharyngeal cancers independent of tobacco and alcohol
(8).
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Human Papilloma Virus (HPV) as a risk factor for head and neck cancer has also gained
significant attention over the past several years. While the significance of HPV and
oropharyngeal squamous cell carcinoma has been well defined, the role within oral cavity
squamous cell carcinomas continues to show little effect. The identification of
transcriptionally active HPV infection from transient infection is associated with p16
positive staining, which is a surrogate of the E7 oncogene (9). While many p16 positive
tissue samples are identified when evaluating surgical specimens of OSCC, significance
is still unknown (10). This is in contrast to p16 positive lesions of the oropharynx, which
tend to occur in younger, non-smokers, is more responsive to chemo and radiation
therapy, and has a better prognosis than non-HPV OPSCC (11). For Squamous cell
carcinoma of the lip, fair complexion and sun exposure, often associated with an outdoor
occupation, are major risk factors. While the survival of other SCC of the head and neck
are rather low, 5 year survival for lip SCC is around 90% (12).
1.1.3 Prognosis
It is often noted that despite advances in management, the 5-year survival of oral
squamous cell carcinoma is still only 50% which has remained relatively unchanged over
the last several decades. While therapeutic modalities have improved, the relatively
stable measure of outcomes is likely due to the late stage of initial diagnosis (13). Early
detection and management of OSCC leads to statistically significant better outcomes as
was identified by Gomez et al in their 2009 meta-analysis (14). It has been reported that
there is significant improvement in 5-year survival for stage 1 disease relative to stage 4
(15). Interestingly, in a retrospective database analysis conducted by Cheraghlou et al
from Yale in 2019, they report that survival has increased significantly over the last

4
several decades. They note that for early-stage disease, 3-year survival has risen from
78.0% from 1973-1980, to 92.2% from 2011-2014. Additionally, they report that patients
with late stage disease have also seen improvements over those same time frames from
51.9% survival to 70.3% (16). This must be interpreted carefully as it is 3-year survival
and not 5-year survival.
In addition to survival outcomes, quality of life (QoL) outcomes are also important. In a
study by Gurney et al, eighty seven patients with previous treatment of their head and
neck cancer were asked to participate in a survey utilizing a quality of life questionnaire
asking about domains including eating, speech, emotion and pain. Of the 87 patients, 71
had carcinoma of the oral cavity, though there was no statistical difference in QoL based
on site of primary tumour. Interestingly, patients with early-stage carcinoma at the time
of diagnosis scored statistically higher QoL scores in the eating domain. Emotion,
Speech and pain were no different. Patients that had recurrence, complications, or
gastrostomy tubes all scored lower (17).
As of the 1990s, a concerted effort was made to standardize treatment of OSCC, with the
advent of nationally available guidelines first printed in 1997. The goal was to enhance
and control cancer treatment by developing protocols for management. This would allow
for proper allocation of resources for efficient care (18). In addition, patients are
funnelled toward high volume centres with dedicated head and neck oncology teams
which independently improve outcomes (19).
1.1.4 Clinical identification
Appropriate diagnosis of OSCC requires a thorough history, physical exam, imaging and
tissue biopsy. Early detection and management of OSCC leads to statistically significant
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better outcomes as was identified by Gomez et al in their 2009 meta-analysis. They found
that the early detection of oral lesions showed a greater difference in prognosis and
outcome than oropharyngeal lesions, likely due to early metastasis of the oropharyngeal
lesions (14). The reliability of symptoms alone for early detection is low, as many
patients present with vague symptoms (20). In this study, no symptom complex was
reliable in determining early oral squamous cell carcinoma. Glottic cancer was the only
head and neck cancer subsite that was detected early because of symptomatology. It was
also reported that the duration of symptoms was not indicative of the time of actual tumor
presence. In another study by Grunfeld, 17 consecutive patients diagnosed with oral
squamous cell carcinoma were interviewed, regarding their beliefs about symptoms and
their decision to seek medical assessment. After self-discovery of the symptoms, delay
ranged from 1 to 48 weeks before seeking help. 24% of patients in the study waited
longer than 3 months before seeking help. It was found that oral symptoms were often
interpreted as minor and a misunderstanding of how oral squamous cell carcinoma
presents led to the delay. Socioeconomic barriers were also mentioned by some as
reasons for delay. Many reported changing their diet, or self medicating in hopes of
improvement (21). Symptoms of OSCC include painless neck mass, loose teeth,
nonhealing ulcers, nonhealing extraction sockets, and pain (4). When a tumour is
identified it can present in one of several typical presentations; exophytic, which grow
outward, endophytic which grow primarily inward, and ulcerated, which has lost
epithelium (22).
Once a lesion within the oral cavity is identified, a tissue biopsy is required for
histopathologic assessment and diagnosis, including low or high grade differentiation,
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and extent of invasion. 5 mm increments have been identified as significant with respect
to depth of invasion in that it effects the staging and treatment of the patient (23). High
grade tumours are those with poorly differentiated cells found on histological assessment.
Further imaging studies such as computed Tomography (CT), Magnetic Resonance
imaging (MRI), Ultrasound (US) and Positron Emission Tomography (PET) are required
to formulate the Stage of the cancer based on TNM staging protocols established by the
American Joint Committee on Cancer. The staging is dependant on the location of the
primary, its size and involvement of adjacent structures, nodal involvement and the
presence of distant metastases, the most common of which are found in the lungs or
bones (22).
1.1.5 Management
Definitive management for OSCC involves surgical resection, with the potential for
adjuvant radiation and chemotherapy. The treatment plan is dependent upon the TNM
stage of the OSCC which is based on the size of the primary tumor, the extent of spread
both locally and into adjacent structures, the depth of invasion, whether or not positive
margins were present on the surgical specimen, and whether or not re-resection is
possible. Nodal involvement and distant metastases further comprise the stage, and it is
this system that best correlates with 5 year survival (24)(23).
Surgery includes resection of the primary tumour. Additionally, depending on the
severity of the disease, a neck dissection to remove lymph nodes, and reconstruction,
potentially involving free tissue transfer, may be required. Increasing severity of disease
requires more aggressive therapy, therefore, early intervention results in less invasive
management, better survival and improved quality of life (24). Surgical resection of the
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tumour aims to achieve a 1.5 cm margin around the tumour if possible. If bone is
involved, partial or complete resection of the bone is required to achieve clear margins
(25). Unfortunately up to 45% of patients present with neck node involvement, and as
such surgical resection of lymph nodes is required (26). The extent also depends on the
location and amount of involvement. Depending on the site and extent of the primary
tumor, modifications of the pattern of neck dissection can be carried out. Neck
dissections can be selective, removing specific levels of lymph nodes, to radical, which
involves all nodes, the submandibular gland, the tail of the parotid and sensory branches
of the cervical plexus (27) (28). Definitive management of the neck is important as many
studies have pointed out that cervical lymph node metastases is the most important
prognostic indicator in these patients (29).
While surgical treatment is the modality of choice for initial care of oral cancer, radiation
can be used alone, with surgery or with chemotherapy depending on the initial
presentation and course of the management of the oral cancer (30). Standard treatment
protocols involve 2 Gy/fraction, for 35 fractions for a total of 70 Gy. Hyper-fractionation
has also proven successful and tolerable for patients. 1.2 Gy is delivered twice daily for
35 days, totalling 81.6 Gy. This was compared against standard treatment protocols in a
large multi-center trial, which demonstrated improved locoregional control and survival
at 5 years post treatment. It was also shown that risks of complications were not
significantly different between the study populations (31). Postoperative radiotherapy is
used in cases of advanced local disease, or multiple lymph node involvement (25). When
used post operatively, radiation therapy lowers recurrence both locally and in the neck,
and increases survival (32). In a study by Lavaf et al, 8795 patients who underwent
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surgery alone or combined surgery and radiation therapy, were evaluated with a median
follow up of 4.3 years. Adjuvant radiation therapy improved 5-year survival with 43.2%
survival in the RT group as compared to 33.4% in the surgery alone group (33).
Radiation therapy is not without its complications. Radiation toxicity can include
mucositis, esophagitis, xerostomia, pharyngitis, odynophagia and dysphagia. While these
are troublesome, they are not life threatening (30). Osteoradionecrosis (ORN) of the jaws
a relatively rare complication with variable morbidity. By definition, it is exposed
irradiated bone that fails to heal over a period of 3 months without evidence of local
recurrence (34). A study by Aarup-Kristensen et al in 2019 reports an incidence ORN of
only 4.2%. (35). With improvement in delivery techniques, the incidence of ORN is
decreasing (36). While major risk factors for the development of ORN include
mandibular surgery and high doses of radiation to large volumes of the mandible, the
exact threshold is not well defined. In a study by Lee et al in 2009, 198 patients with oral
and oropharyngeal squamous cell carcinoma were evaluated who had undergone
radiation therapy over a 10-year span, from 1990, to 2000. This study found that patients
who had a mandibular procedure such as an extraction, were at increased risk, as were
those who had received on average, greater than 54 Gy (37). The study by AaurpKristensen et al reported a mean dose of 39 Gy for their irradiated patient cohort, and
reported that those that developed ORN received higher than average doses of radiation
though fail to delineate a threshold (35). Nabil and Samman conducted a systematic
review in 2010, and they report that the greatest risk belongs to those that have a tooth
extracted in the field of radiation, as well as those that receive greater than 60 Gy (38).
Despite surgical excision and radiation therapy, systemic therapy can be required to
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improve outcomes. Some head and neck cancer patients with perineural invasion, oral
cavity cancer, positive surgical margins, multiple positive lymph nodes, and
extracapsular spread of lymphatic disease are at greater risk for poor outcomes as
compared to others (25). Systemic therapy refers to chemotherapy and immunotherapy
which continue to play an increasingly important role in treatment of patients (39). These
agents can be administered before, during or after loco regional management which
equate to induction, concomitant and adjuvant chemotherapy respectively (40).
Additionally, these agents can been used alone or together with radiation therapy, as
radiation sensitizers (39). Numerous studies have evaluated the utility of systemic agents.
Assessing 70 randomized trials from 1965 to 1993, Pignon et al conducted a metaanalysis evaluating the effect of chemotherapy on head and neck squamous cell
carcinoma. Studies evaluated the efficacy of chemotherapy, as well as the timing of
chemotherapy. While the data did demonstrate an absolute survival benefit of 4% at 2
and 5 years, there was considerable heterogeneity within the data. Therefore, conclusions
could not be drawn based on this data (41). The group repeated the study and published
in 2009. They included 24 randomized trials from 1994-2000 (40). In this meta-analysis,
concomitant chemotherapy demonstrated benefit over induction chemotherapy with an
absolute benefit of 6.5% at 5 years. Chemotherapy in conjunction with radiotherapy
shows increased benefit.
Two large trials were then carried out which evaluated the use of cisplatin in addition to
standard therapy of surgery and post-operative radiation therapy (PORT). These studies
were important for further characterizing which patients would go on to benefit from the
chemotherapy as compared to those that would not(42) (43). These too demonstrated
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improved locoregional control and distant disease free survival, while the Cooper et al
study demonstrated an improvement in overall survival (42).Cetuximab is another
chemotherapeutic utilized to improve long term outcomes in patients with locoregionally
advanced squamous cell carcinoma of the head and neck. It is a monoclonal antibody
against epidermal growth factor receptors (39). In a study published in the New England
Journal of Medicine in 2006, it was shown to significantly improve locoregional control
when used with radiation therapy as compared to radiation therapy alone (24.4 months vs
14.9 months) (44). It also demonstrated improved overall survival with a median of 49.0
months when combined with radiation therapy as compared to 29.3 months for radiation
therapy alone. In addition to these agents, 5-fluorouracil (5-FU), docetaxel, paclitaxel,
hydroxyurea, and carboplatin have been studied and used in various combinations for
post-operative and induction chemotherapy (39).
1.1.6 Follow up
Long term follow up for these patients is required as they are at increased risk of new
OSCC either at the site of the original excision, or at a different site (45). This highlights
the need for continued follow up with a medical professional. In a study conducted by
Thomson, Goodson and Smith, 99 patients that developed cancer from a pool of 590
patients with OPMLs were closely reviewed. Of the 99 that developed OSCC, 28 of these
patients went on to develop malignant lesions at the same or a different site, supporting
the argument for long-term follow up (46).
1.2 Normal oral mucosa
The oral mucosa is roughly analogous to the skin, in that there is an epithelium overlying
connective tissue. In the oral cavity, the epithelium is comprised of stratified squamous
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cells, which are situated on a connective tissue base, referred to as lamina propria. The
morphology of the epithelium varies based on location and functional demands within the
oral cavity, serving several purposes including immunological barrier, protective
mechanical barrier, and host specialized cells such as glands and nerves for lubrication
and enhanced perception(47).
The cells of the epithelium are the ones that are considered when discussing oral
premalignant lesions. In this case, the layers of the mucosa are dependant on their
location; in areas where masticatory forces are present, such as the dorsal tongue, palate
or gingiva, the surface is lined by a layer of ortho or parakeratin and as such is called
masticatory mucosa. Non-keratinized, lining mucosa, allows for improved flexibility and
is found at the floor of mouth, soft palate, cheeks, lips, alveolar mucosa and vestibule
(Figure 1.1) (48)(49). Additionally, the tongue is covered by a specialized epithelium
which is both keratinized and nonkeratinized and contains papilla, responsible for special
features of the tongue surface (48)(50). The relative amount of each type of epithelium
that comprises the oral mucosa is approximately 25% masticatory, 60% non-keratinized,
and 15% specialized epithelium (51)(48).

Figure 1.1: Demonstration of types and anatomic location of mucosa within the oral
cavity. This figure was originally published in Squier CA, Kremer MJ. Biology of oral
mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;52242(29):7–15. This figure is
being reproduced for educational purposes only and not for commercial use. The figure
is included in the MSc. dissertation with attribution.
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The layers of squamous cells within the mucosa represent a progressive maturation from
basal membrane to superficial layer, with the most superficial layer becoming cytokeratin
filled cells called keratinocytes(47). Interestingly however, the differentiation is not
solely dependent on the departure away from the basal lamina, as cells that are prevented
from migrating and remain affixed in place, can still differentiate (47). The layers within
the masticatory mucosa from deep to superficial include: stratum basale (basal layer),
stratum spinosum (prickle cell layer), stratum granulosum (granular cell layer), and
stratum corneum (keratinized layer) (Figure 1.2). Only the basal and prickle layers are
present in the lining mucosa. Unlike epidermis, there is no stratum lucidum (47).
Within the basal layer, are progenitor cells that are present at or near the basal lamina in
thin and thick epithelium respectively, and tend to occur in clusters at the depth of the
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rete ridges (48). These progenitor cells give rise to daughter cells that either stay within
the basal layer to maintain progenitor potential of the tissue, while the other daughter cell
becomes an amplifying cell, which undergo mitosis, increasing in number and
maturing(48)(52). As the cells mature they migrate toward the surface and eventually
desquamate(48). These cells are at the least differentiated stage of their maturation with
limited organelles for secretion and protein production. There are organelles responsible
for production of components of the basal lamina, tonofilaments and keratin (47).
Superficial to the basal layer is the stratum spinosum. This layer is several cells thick
demonstrating further maturation and differentiation as the cells migrate. Intracellular
processes required for the production of new proteins such as cytokeratins are expressed.
The proteins involved in intercellular adhesion, such as desmosomes also increase in
number, and as the cells pull away at nonadherent portions of the cells, contributes to the
spines which appear on microscopy. The cells of the parabasal layer are characterized by
a combination of features of the prickle layer and basal layer, and are still capable of
replication (47).
The next layer cells are larger and flatter than the deep layer, and are regarded as the
granular layer. Within this layer, most organelles are gone, and the cytoplasm is
comprised of tonofilaments and tonofibrils, with an increase in the number of granules
called keratohyaline granules. These contain profilagrin, the precursor to fillagrin, which
holds the keratin filament network together. Additionally, the granules that are present in
the prickle layer now fuse with the lipid membrane and release their contents into the
intercellular space. This is a lipid rich material which helps prevent water loss and
improve impermeability, while involucrin and loricrin stabilize the cell membranes (47).
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The outermost layer is the keratinized layer, in which the cells have matured, and will
eventually desquamate. These cells have lost all intracellular organelles, with their
intracellular content mostly comprised of keratin.
Figure 1.2: Layers of keratinized mucosa. Modified from Squier CA, Kremer MJ.
Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;52242(29):7–
15. This figure is being reproduced for educational purposes only and not for commercial
use. The figure is included in the MSc. dissertation with attribution.

Homeostasis within the epithelium is maintained by a balance between cell proliferation,
and apoptosis, desquamation of the surface layer of cells and to a lesser extent, necrosis.
This is evident as the epithelium continues to grow throughout life, yet the number of
cells within the epithelium stays relatively constant in normal healthy tissue. Regulation
of these processes is complex, with a significant number of molecules involved. In
general, three types of receptors are involved in proliferative or inhibitory pathways;
Kinases, G protein coupled receptors, and steroid binding molecules which have the
ability to move into the nucleus once bound, to bind and alter gene expression (53).
Kinases and phosphatases are two classes of enzymes which regulate a number of cellular
processes via the transfer of phosphate groups onto organic molecules. These enzymes
have opposing function, with the kinases acting to phosphorylate their target molecules,
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either Tyrosine residues, or Serine and Threonine residues, while the phosphatases
dephosphorylate them (53). Both mechanisms are involved in the regulation of mitosis,
and apoptosis.
Keratinocyte cell proliferation and rate of differentiation within the epithelial layer is
dependant upon the location of the cells in the oral cavity and whether they are in the
keratinized or non-keratinized mucosa. Lining epithelium in the floor of mouth and
ventral tongue having the greatest rate of proliferation, and the keratinized tissue of the
gingiva and palate having slower rates (5). Using calculations and results from Thomson
et al, the turnover time, or time it takes for a cell to mature through the epithelium and
shed, ranges from 14-24 days in the oral cavity, which is faster in the non-keratinized
than keratinized tissue (48). Sulcular epithelium, immediately adjacent to the tooth, turns
over the most rapidly, with a turn over time of approximately five days (47).
1.3 Oral potentially malignant lesions
1.3.1 Overview
Oral potentially malignant lesions are relatively common morphological alterations to the
oral soft tissue with an increased risk of dysplastic and cancerous transformation relative
to normal epithelium (54). The definition is based on the following: 1) In longitudinal
studies, areas of tissue with certain alterations in clinical appearances identified at the
first assessment as ‘precancerous’ have undergone malignant change during follow-up. 2)
Some of these alterations, particularly red and white patches, are seen to co-exist at the
margins of overt oral squamous cell carcinomas. 3) A proportion of these may share
morphological and cytological changes observed in epithelial malignancies, but without
frank invasion. 4) Some of the chromosomal, genomic and molecular alterations found in
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clearly invasive oral cancers are detected in these presumptive ‘precancer’ or
‘premalignant’ phases (55).
1.3.2 Epidemiology
Lesions which are now considered to be potentially malignant are numerous and
identified in table 1.1. In addition to those included on the list, a new set of lesions have
been also considered OPML since 2017. These include: chronic hyperplastic candidiasis,
oral lichenoid lesions, exophytic verrucous hyperplasia, and oral lesions of graft versus
host disease (56). Information is somewhat limited on the prevalence of these disorders,
but overall, based on a systematic review in 2018 conducted by Mello et al, the pooled
prevalence of oral potentially malignant lesions was 4.47%. There is variability of the
prevalence, occurrence geographically, and gender with each of the lesions. Submucous
fibrosis was the most common with a prevalence of 4.96%, followed closely by
leukoplakia, with a prevalence of 4.11%. Erythroleuloplakia was rare, with a prevalence
0.17% (57). A study conducted in 1987 out of Sweden evaluated the prevalence of all
white patches inside the oral cavity to be 24.8% in Swedish adults, however, when reevaluated with newer definitions considered, prevalence was only 3.6% (56)(58).
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Table 1.1: List of oral potentially malignant lesions. From El-Naggar AK, Chan J,
Grandis J. World Health Organization Classification of Head and Neck Tumours. Vol. 9.
2017.
Oral Potentially Malignant Disorders:
Erythroplakia
Erythroleukoplakia
Leukoplakia
Oral submucous fibrosis
Dyskeratosis congenita
Smokeless tobacco keratosis
Palatal lesions associated with reverse smoking
Chronic candidiasis
Lichen planus
Discoid lupus erythematosus
Syphilitic glossitis
Actinic cheilitis (lip only)
From the review by Mello, oral potentially malignant lesions were seen in greatest
number in Asian populations, with an overall incidence of 10.54%, with leukoplakia
occurring with a prevalence of 7.77%, and oral submucous fibrosis at 4.96%. The lowest
prevalence was in North America, with a prevalence of 0.11%, while in the Caribbean
and South America, the prevalence is 3.93% with leukoplakia and erythroplakia
occurring with a prevalence of 3.32%, and 0.32% respectively. For Europe, the
prevalence was 3.07%, while in the middle east it was 3.72%. Male and female patients
represented 59.99% and 39.89% of cases respectively (57).
1.3.3 Risk factors
The occurrence of these lesions appears to be dependent upon gender, tobacco habits and
age according to several studies, however, research on these tend to be observational and
retrospective. The data is heterogeneous and it is difficult to control for all variables (59).
There are a limited number of studies focusing on the characteristics of OPMLs, which
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tend to focus on very specific populations. Patients with oral premalignant lesions from
developing nations tend to be identified 5-10 years earlier than developed nation, where
individuals tend to be identified in their fourth to seventh decade of life (59). Gender
also demonstrates variability between males and females and appears to depend on the
population evaluated. In a retrospective chart review from India in 2019, 630 patients
were evaluated, 375 of which had an OPML or OSCC. Patients attended either a regional
dental school, or one of twenty dental clinics. The male to female ratio was 2.28:1, and
the average age was 42.64 years with a range from 18-72 years. Submucous fibrosis was
the most common OPML occurring in 49.33% of the patients, followed by leukoplakia,
which occurred in 29.33% of the 375 patients. The buccal mucosa was the most common
site, with 33.01% followed by the tongue and floor of mouth with 22.53% and 14.92% of
the lesions respectively. 65% of the patients had at least one risk factor such as tobacco
use, alcohol consumption or areca nut (60).
In another retrospective review, all cases with the diagnosis of OPMLs by the Oral
Pathology lab at the University of Rio de Janeiro were evaluated. A total of 684 patients
were included with OPMLs, with 392 (57%) being female. The age range of patients was
seven to 100 years old, with 82% of the patients being between 41 and 82 years old. The
mean age for males was 55 years old, while females was 60 years old. Within the oral
cavity, the most common site for OPMLs was the lateral boarder of the tongue, with 23%
of lesions occurring there. The lower lip and buccal mucosa were second and third most
common, occurring in 20% and 19% respectively. 82% of the lesions were leukoplakia.
None of the lesions were considered pure erythroplakia. 53% of the patients had a
tobacco use history, and 30% reported alcohol consumption. This was more frequent in
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males in both cases (61).
Yet another study evaluating a number of oral white lesions in 20333 Swedish adults,
24.8% of patients had a white lesion in their mouth. When cheek and lip biting and
smokers palate were excluded, the prevalence dropped to 20.1%. The lesions were found
more frequently in males. With respect to location, the commissures and buccal mucosa
were the most frequent site for leukoplakia (62).
1.3.4 Leukoplakia
Leukoplakia is a clinical term describing a white plaque of questionable risk having
excluded known diseases or disorders that carry no increased risk of cancer. Examples of
non-leukoplakias include frictional hyperkeratosis, leukoedema, and white sponge nevus
(55). The term is meant to convey information between the clinician and pathologist, and
does not include any information regarding histological features, such as acanthosis,
hyperkeratosis, dysplasia, or a combination of any of the three (55). Historically,
leukoplakia has been used interchangeably with the dysplasia, however this is incorrect
and should be differentiated (63).
Causes of leukoplakia have been debated for many years. While tobacco use, areca nut
and alcohol have all been strongly linked to malignancy, their role in the development of
leukoplakia is less well known. It has been shown in a number of studies that lesions are
more frequent in smokers, and that when smokers stop using tobacco, a number of lesions
regress or resolve (64). This is contested in a recent review which stated that newer
studies with better statistics indicate that there is not a cause and effect relationship
between smoking and leukoplakia (63). Likewise, alcohol consumption and its
relationship with leukoplakia is reviewed in this same article. Much the same argument is
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made, in that a cause and effect relationship could not be established. In addition, they
further note that amount of alcohol consumed may be a factor (63).
There are 2 general classifications of leukoplakia, homogenous and non-homogenous
(65). Homogenous is grossly uniform, smooth, white and grossly flat. With respect to
non-homogenous, there appears to be roughly 3 variants: speckled, nodular and
verrucous. The speckled variety is often referred to as erythroleukoplakia, which is a
predominantly white lesions, with red patches interspersed. The nodular lesions are
polypoid, while the verrucous lesions are corrugated and appear thicker than homogenous
leukoplakia. In a retrospective study of 216 patients with OPML conducted over a 12year period, it was noted that clinical diagnosis was significantly associated with the risk
of malignant transformation, and therefore points to the importance of identifying high
risk lesions. They note that non-homogenous lesions had a 4.2 times greater risk of
dysplasia as opposed to homogeneous lesions (66).
1.3.5 Erythroplakia
Erythroplakia is a rare epithelial lesion often not included in the category of oral
potentially premalignant lesions likely due to the scarcity of its occurrence. A large study
by Mehta where a total of 59 915 individuals were evaluated, only 9 cases (0.02%) were
found to be erythroplakia (67). This was relatively similar to a survey of 6000 villagers
in Burma in which 5 cases were diagnosed with a prevalence of 0.83% (68). When
discovered in the oral cavity, erythroplakia tends to have significant features concerning
for advancement to oral squamous cell carcinoma (69). One particular study of a series of
58 cases of erythroplakia found that 91% of the lesions were either already invasive,
carcinoma in situ, or severe epithelial dysplasia (70). When discovered, these lesions
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should be treated as malignancy.
1.3.6 Malignant transformation
The malignant transformation rate of oral leukoplakia has been reported to be within the
range of 3.54% to 9.70% (71)(72). 9.70% was established in a meta-analysis of
prevalence studies in 2020 that looked at a total of 23 489 lesions. In addition to the
transformation rate in general, they noted the high heterogeneity based on geographic
region. They therefore ascertained that country of origin was an important risk factor for
malignant transformation. This should be viewed cautiously though as there is significant
variability of habits by geographic region as well (71). The lower transformation rate of
3.54% was from a 2016 meta-analysis in which 11 423 lesions were identified (72). The
2016 study was restricted to observational studies, as well, they applied a consistent
definition of oral leukoplakia to older studies, limiting the total number of lesions that
truly represent oral leukoplakia.
Further evaluation of the data within these studies revealed a gender difference in
malignant transformation with the 2020 study reporting a transformation rate of 7.6% in
males, and 12.6% in females (71). This is corroborated by the 2016 study, which also
reports a higher transformation rate among women based on the analysis of twelve
studies. The cause of this discrepancy is unknown (72).
Transformation rate and time to follow up was evaluated, which showed that the longer
the time to follow up, the greater the chance of malignant transformation. In addition,
time to malignant transformation was included as an outcome of interest, which was
reported as 11-132 months. The difficulty with this number is that there was a high
degree of heterogeneity, making it impractical to complete a meta-analysis of this data
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(71).
Age and malignant transformation rate was also considered with 11 of 34 papers
reporting the age of the patient at diagnosis (72). Amongst the included studies, there was
considerable heterogeneity in age and transformation rate. However, in conjunction with
other studies, evidence does support the notion that the greater the age, the greater the
risk of malignant transformation (59). A Swedish study found the greatest rate of
transformation occurred in patients 70-89 years at 7.5% of patients and only 1% in those
under 50 years old (73). In another article, it was found that the peak incidence of
leukoplakia occurred in the sixth decade, and the greatest incidence of transformation to
carcinoma was in the seventh decade(74). It may be speculated that changes in the
immune system with advancing age may contribute to the increase in transformation
rate(75)(76).
The duration of the lesion is also a significant factor that appears to correlate with
malignant transformation rate (59). It appears that the greatest risk for malignant
transformation occurs within the first 5 years of the development of the leukoplakia.
Vigilance is required beyond 5 years however, as the risk of malignant transformation
still exists, with one study even noting malignant transformation of oral leukoplakia 16
years after diagnosis of the original lesion(77).
Malignant transformation rate and site of the oral leukoplakia has also been evaluated. It
seems the most frequent location for the development of oral leukoplakia is the buccal
mucosa, however, the most likely site for malignant transformation is the floor of mouth
and lateral borders of the tongue, as oral squamous cell carcinomas appear
disproportionately at these sites (59). This however is not uniform in all studies. While
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some report similar findings with high risk sites for transformation amongst patients from
Denmark, Hungry, England and California; other studies show no association between
site and malignant transformation in patients from Netherlands (59). Increased malignant
transformation at the floor of the mouth and ventrolateral tongue may be due to the
pooling of carcinogens in this area where the mucosa has the greatest permeability
(78)(64).
Clinical appearance of the leukoplakia seems to be a differentiating factor for those
lesions at greater risk of becoming malignant. As previously mentioned, leukoplakia can
be described as homogenous or non-homogenous. These have also been referred to as
simplex verrucous or erosive (74). The literature supports the notion that the nonhomogenous leukoplakia carries an increased risk of malignant transformation relative to
the homogenous group(59).
A limited number of studies have also found size of the lesion to be a relevant factor in
malignant transformation(69). In the Netherlands, it was found that the greatest
transformation rate was thought to be most likely in lesions greater than 200 mm2 while
in Denmark, lesions greater than 5.5cm2 were thought to be at increased risk(79)(80).
Additionally, an Irish study found that patients with single lesions were at greater risk of
transformation than those with multiple or confluent lesions. As such, it appears that
larger singular lesions carry a greater risk of transformation as compared to smaller
lesions, or those with multiple lesions (81).
Interestingly, the effects of tobacco use and malignant transformation of oral leukoplakia
are not firmly established as there are conflicting conclusions about the existing data.
While several studies highlight the risk of developing oral leukoplakia in tobacco users as
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significant, the malignant transformation of oral leukoplakia to oral squamous cell
carcinoma, is not as clearly defined or supported by the data(59)(69)(82)(83). For
example, Silverman found that of the patients who developed oral leukoplakia, 74% used
tobacco, however, only 47% went on to develop oral squamous cell carcinoma. Of the
non-smokers in the group, those that smoked and then quit did demonstrate a reduction in
their cancer risk (3). As such, it appears that tobacco use and oral leukoplakia maybe
linked, however, the transformation from oral leukoplakia to squamous cell carcinoma is
not as strongly linked as one would expect. In fact, oral leukoplakia that develops in
patients with no history of tobacco use, are often referred to as idiopathic leukoplakia,
appear to be at a greater risk of malignant transformation(59)(69)(3)(73)(84)(64). There
may be a difference in leukoplakia that is caused by an irritant, and those that arise
spontaneously.
Dysplasia within the biopsy specimen of leukoplakia or erythroleukoplakia has an
increased risk of malignant transformation, however this is contested. While the
classification of dysplasia is problematic and will be discussed later, in general, several
studies have reported oral lesions which demonstrate dysplasia histologically, carry a
greater risk of malignant transformation than lesions that do not demonstrate dysplasia.
The risk of malignant transformation as noted by Burkhardt and Maerker in 1978 has
been noted to be 3%, 4% and 43% for mild, moderate and severe dysplasia (64). With
respect to malignant transformation, this is corroborated in the study by Silverman, in
which 36% of dysplastic lesions progressed to malignancy. Interestingly however, 16%
of leukoplakias that did not demonstrate dysplasia on histological examination, also
progressed (3). This is also supported by Schepman, who in their study 166 hospital
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based patients, those with moderate and severe dysplasia on their histological evaluation
had a statistically significant increased risk of malignant transformation (84).
Additionally, another study reported that lesions with moderate or severe dysplasia had a
2-3 times increased risk of malignant transformation relative to hyperkeratosis or mild
dysplasia (85). However, not all studies agree. In 2009, a group from Italy studied 207
patients with long term follow up and failed to find any significant value in any grade of
dysplasia, with respect to malignant transformation relative to non-dysplastic lesions
(86).
1.3.7 Management
Management of oral leukoplakia is not certain. Some lesions progress while others do
not, and some lesions recur after treatment, while others do not and there is no clear
method of differentiating which lesions will benefit from invasive management (87).
Options for management include watchful observation, surgical resection, laser ablation,
topical and systemic agents and photodynamic therapy (87). For surgical management,
the logic is that removal of the lesion decreases the risk of malignant transformation. For
NSAIDs, cyclo-oxygenase is inhibited, which may prevent the production of
prostaglandins that could contribute to malignant transformation. Chemotherapeutics are
intended to destroy cells which have already become neoplastic (88).
Removal of oral leukoplakia by either surgical excision or laser ablation has not
convincingly demonstrated a reduction in the malignant transformation rate (86)(79)(84).
Therefore, a patient may undergo a surgical excision that has considerable morbidity but
gain no true benefit with respect to risk mitigation. This is however contested, and
surgical excision with mitigation of other risk factors can have a positive effect on
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mitigating the risk of malignant transformation(82). Of 520 patients with leukoplakia
who received some form of treatment, those that had removal of etiological factors and
surgical excision of the lesion showed the greatest resolution as compared to nonsurgical
methods such as topical agents. In contrast, Einhorn and Wersall found an increased
transformation rate amongst those who underwent surgical excision (73). When
compared to the nonsurgical management group at 2, 5 and 15 years, malignant
transformation amongst the excision group was 1.6%, 2.3% and 4.6% versus 0.4%, 1.1%
and 2.5% respectively. This paper does mention that there is likely selection bias as
lesions at greater risk of malignant transformation are typically the most concerning
lesions clinically, and therefore it was these lesions that likely underwent excision. In a
cohort study from the UK, 100 patients were followed for 10 years following laser
ablation of leukoplakia in the floor of the mouth. Of the 100 patients, 62 patients
remained disease free, while 17 went on to develop leukoplakia at the same site, 14
developed leukoplakia at another site, 5 developed OSCC at the same site and 2
developed OSCC at a different site (89).
Photodynamic therapy is a method of management for oral leukoplakia considered to be
nonsurgical. There are 3 components 1) a light source, 2) a photosensitizer, 3) tissue
oxygen. The photosensitizer is applied then a light source is used. This results in the
production of reactive oxygen species (ROS), which causes oxidative damage to the
premalignant and malignant cells (90). Two recent systematic reviews, completed in
2015 and 2019 revealed that the photodynamic therapy was effective at either eliminating
or reducing the lesion, however, in both cases, recurrence at the original site was 36%
and up to 60% respectively. Overall malignant transformation rates were not a part of
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either of the reviews (91)(90).
With respect to topical agents and chemotherapeutics, a Cochrane review from 2016 was
conducted. In this review, beta carotene, NSAIDs, Vitamin A topical bleomycin and
herbal remedies were evaluated. The outcomes for studies included malignant
transformation and resolution of the lesions themselves. While Vitamin A and beta
carotene may effectively improve the leukoplakia, none were overly effective for
prolonged resolution or prevention of malignant transformation (88).
1.4 Dysplasia
1.4.1 Introduction
Histological diagnosis of oral lesions is the gold standard for evaluating and diagnosing
dysplastic lesions. Dysplasia is a precancerous lesion of stratified squamous epithelium
characterized by a continuum of cellular atypia, with loss of normal maturation and
stratification. Carcinoma in situ indicates that the atypia and abnormal maturation of
stratification is at or near full thickness (92). Varying degrees of dysplasia exist and
these differences are stratified into mild moderate or severe dysplastic changes by the
WHO grading system (93). The grade into which the specimen is characterized as is
dependant upon the relative degree of change from the basal layer to the epithelium. The
characteristic histological changes that are evaluated are present in table 1.2.
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Table 1.2: Criteria for identifying and grading oral epithelial dysplasia.
Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia
classification systems: Predictive value, utility, weaknesses and scope for improvement. J
Oral Pathol Med. 2008;37(3):127–33.
Architecture
Cytology
Irregular epithelial stratification
Abnormal variation in nuclear size
(anisonucleosis)
Loss of polarity of basal cells
Abnormal variation in nuclear shape
(pleomorphism)
Basal Cell hyperplasia
Abnormal variation in cell size
(anisocytosis)
Drop-shaped rete ridges
Abnormal variation in cell shape
(pleomorphism)
Increased number of mitotic figures
Increased nuclear:cytoplasm ratio
Abnormally superficial mitoses
Increased nuclear size
Premature keratinization in single cells
Atypical mitotic figures
Keratin pearls within rete ridges
Increase number and size of nucleoli
Hyperchromasia
When the changes are full thickness and there is a breach of the basement membrane,
squamous cell carcinoma is diagnosed (24). These changes are on a continuum and are
simply a continuation of the genetic changes responsible for dysplasia. Many of the
OSCCs are well differentiated or moderately differentiated, therefore products such as
keratin, in the form of keratin pearls, develop. In these cases, identification of the
invasion of epithelial cells is more obvious, where as poorly differentiated carcinomas
can have cells which are spindle shaped, or sarcomatoid, which requires special staining
techniques to correctly identify the cells as squamous epithelium in origin (24).
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Table 1.3: Grading scheme for oral epithelial dysplasia. El-Naggar AK, Chan J,
Grandis J. World Health Organization Classification of Head and Neck Tumours. Vol. 9.
2017.
WHO dysplasia grade
Binary grade
(3tier)
(2 tier)
Mild dysplasia
Low Grade
Moderate dysplasia
High Grade
Severe Dysplasia
1.4.2 Grading systems
The grading of dysplasia within a specimen is based on the microscopic evaluation of
hematoxylin and eosin (H&E) prepared tissue samples, and subjective interpretation of
the above features, and their distribution within the epithelium. Mild epithelial dysplasia
is considered to demonstrate these architectural features, but the features are confined to
the lower third of the specimen, and the cytological changes are relatively minimal.
Moderate dysplasia is a continuation along the spectrum of histological changes in the
epithelium, with the changes extending into the mild third of the epithelium, or, having
sufficiently cytological atypia that the specimen is considered to have moderate dysplasia
even if the dysplastic changes do not enter the middle third of the epithelium. Severe
dysplasia is found when the architectural changes extend to the most superficial third of
the epithelium, or that the cytological changes are significant enough that it is still
considered despite the architectural changes not extending into the superficial third.
When the tissue is significant for these changes through the whole epithelium, but
invasion beyond the basement membrane has not occurred, carcinoma in situ is used (94).
In addition to the WHO classification of oral epithelial dysplasia, there is also a binary
system based on the same criteria that has been proposed and assessed for utility (95). A
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pilot study was conducted in which 28 samples with known outcomes was conducted. 14
tissue samples progressed to cancer, with 14 that did not. The specimens were assessed
using the WHO classification system and then evaluated based on the same criteria. It
was found that 4 histological and 4 cytological changes was the threshold for classifying
a tissue specimen as high risk. This was then tested in a retrospective study, conducted by
the same group in which the pathologists were blindly reviewed 68 tissue specimens,
with known outcomes. It was found that this binary system had greater interobserver
agreement than the WHO classification (Kappa score 0.5, Kappa 0.22 respectively) (95).
This new binary system has been embraced with the high risk cut off of 4 architectural
and 5 cytological changes (96).
Historically, other grading systems have existed, but have not received widespread
acceptance. Smith and Pindborg created a scheme in 1969 where samples were evaluated
based on 13 features as either present or not present, slightly present or markedly present,
based on a comparison to standard photographs. A score was then assigned (97). The
systems flaws however, include the fact that there is no evidence to support the standard
photos, and that it is time consuming, therefore it has not caught on universally (94).
1.4.3 Predictive value of grading systems
While pathologists assessing the tissue tend to favour grading tissue as mild, moderate or
severe dysplasia, it is well known that this is a flawed system due to the subjectivity of
the assignment of these grades. In a Danish study, 4 pathologists were presented with 100
tissue samples and asked to evaluate them as non-dysplastic, mild, moderate, or severe
dysplasia, and carcinoma in situ. The inter-observer agreement, which was grossly the
same regardless of training, was 49-69%,while the kappa values were in the range of 27-
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45% (98). A kappa of this value indicates that inter-observer agreement is generally quite
low.
An American study compared six oral pathologists by having them evaluate 120 prediagnosed lesions. Several months later, they were given 60 of those same tissue samples
to re-evaluate. In the first round of assessment, agreement with the original diagnosis of
the tissue sample was 50.5%, with 90.4% of the diagnoses within one histological grade
of the originally diagnosis. During the second round of evaluation intra-observer
diagnoses was assessed with agreement averaging 50.8%, with 92.4% within one
histological grade of their original diagnosis. The ability for the pathologists to recognize
dysplasia from non-dysplasia was 81.5%, while agreement with themselves with respect
to the same question was 80.3% (99). These numbers indicate that the variability in the
interpretation of the tissue sample is significant.
Inter-observer variability was assessed in another study out of the UK, where the exact
features of the WHO architectural and cytological variables were documented in order to
assess which caused the greatest variation, and those that were most agreed upon within a
given sample. In the study of four pathologists, architecturally the most agreed upon
features included increased number of mitotic figures (kappa of 0.46), drop shaped rete
ridges (kappa of 0.42). With respect to cytoplasmic changes, increased nuclear size and
abnormal variation in cell shape (kappas of 0.21 and 0.20 respectively) were the most
agreed upon. Irregular epithelial stratification, loss of polarity of basal cells, abnormal
variation in nuclear size, atypical mitotic figures, and hyperchromatism were the source
of greatest disagreement (100).
The binary system was also assessed for clinical outcomes. The sensitivity and specificity
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for predicting malignant transformation was found to be 85% and 80% respectively.
Progression free survival for patients considered low grade was 84.8%, while those
deemed high grade had progression free survival of only 20%. This was not compared to
the original WHO grading system. Based on this study, it appears that the original WHO
and binary system are at least comparable, and that there is potential for utility (95).
When the binary and original WHO classification systems were then assessed by
Nankivell et al, it was found that the interobserver agreement was superior to the original
WHO ( kappa 0.59 versus 0.49 respectively), the prognostic ability was similar (101).
While the classification systems regarding oral epithelial dysplasia is not perfect, they are
currently our most used and accepted methods of predicting outcomes. The utility can be
viewed from several metrics: risk of progression to OSCC, cancer free survival and
survival. Few studies have evaluated this as a primary outcome. In an Irish study by
Napier et al published in 2001, 50 patients whose initial biopsy demonstrated dysplasia,
only half developed into OSCC, with a positive predictive value of 0.52 (94). In another
study involving 257 patients with leukoplakia, 22 were found to have dysplasia, 8 of
whom developed OSCC at these sites. The difficulty is that 23 patients without dysplasia
in the leukoplakia went on to develop OSCC demonstrating current difficulty in
predicting transformation (3).
In keeping with these results, Sperandio et al evaluated 1379 patients for 5-15 years who
had been diagnosed with dysplasia. 6/105, 14/76, and 15/38 patients with mild, moderate
and severe dysplasia respectively developed OSCC. 14/1182 nondysplastic lesions
transformed to OSCC (102). Therefore, while dysplasia is an important predictive tool,
the grade of dysplasia does not completely identify those lesions which will transform.
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This has a significant effect on management of these lesions.
1.4.4 Management of oral epithelial dysplasia
Currently, the only method believed to be beneficial in managing dysplastic lesions is
surgical excision. In a Cochrane review that evaluated management strategies for
OPMLs, methods including herbal extracts, topical bleomycin, Bowman-Birk inhibitor,
non-steroidal anti-inflammatory drugs (NSAIDs), Carotenoids, and Vitamin A were
assessed (103). According to the analysis, all of the treatments appeared to be well
tolerated but there is a lack of strong data as to the efficacy of any of them. Surgical
management does appear to decrease the risk of malignant transformation but does not
eliminate it. In a study from Australia, 590 patients with OPLs were evaluated, 88% of
whom had dysplasia and underwent laser excision. Of those with carcinoma in situ and
severe dysplasia, 9% demonstrated persistence and 16% had recurrence (104). Similar
results were discovered by Holmstrup in which 296 lesions were biopsied, 94 of which
were excised, 71% of which had some grade of dysplasia. Recurrence occurred in 13%
and carcinoma developed in 12%(79). These results were in agreement with a
retrospective study in Italy in which 207 patients underwent biopsy, 135 of which had
mild dysplasia, 50 had moderate, and 22 had severe. Over the 16 years of observation,
128 underwent excision, 5 underwent cryotherapy and 74 elected to observe their lesions.
Of the 207 lesions, 39.4% of the lesions disappeared, 19.66% remained stable, 33.7% had
a recurrence and 7.24% developed squamous cell carcinoma. It was reported in the study
that histological grade of dysplasia was not significant for identifying lesions that became
malignant (86). A protocol has been established in Liverpool which attempts to consider
factors such as patient age, location of the lesion, as well as grade of dysplasia as to
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whether an observation as compared to surgical excision is required. Those lesions
deemed higher risk were lesions in non-smokers, were non-homogenous, were on the
lateral border of the tongue, and larger than 200mm2. The goal of the research team was
not to have their protocol established as guidelines, but create further discussion
regarding what they felt was an important subject matter, driving further research (105).
Due to the risk of recurrence of these lesions, or progression from dysplasia to OSCC,
follow up is required. The complicating factor is that due to the variable progression of
these lesions, and our inability to reliably detect which lesions will progress as opposed
to those that will not, there is no consensus as to the frequency or duration of follow up
that is required in patients with dysplasia. It has been suggested that a frequency of every
6 months is satisfactory, but the duration of follow up is unknown, potentially as long as
20 years (106).
1.5 Theories of carcinogenesis: Field cancerization
The theory of field cancerization can help explain malignant transformation regardless of
surgical excision. There are two prominent theories regarding field cancerization. One
theory is that prolonged exposure to carcinogens results in multiple independent tumors
forming due to chronic exposure damaging the cells within the mucosa equally within an
anatomical region. The concept originated in 1953 when oropharyngeal, lip and oral
cavity squamous cell carcinoma tissue samples from 783 patients were reviewed and
several conclusions were made: 1) the seemingly normal mucosa at the margin of a
malignancy was in fact abnormal, 2) multiple independent lesions could be found within
the resected tumour, 3) the development of second primary tumours within the patient
population was high, 4) often, the two separate tumours were from the same anatomical
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space, and 5) the recurrence rate of oral squamous cell carcinoma is high. Of the 783
patients in the study, 88 developed second primary lesions 43 within the same anatomical
region. The research team felt the cells in the anatomic region were exposed to the same
amount and intensity of carcinogen, resulting in greater recurrence than random chance
within these sites. This was further evidence supporting the theory for field cancerization
(107).
The second theory is that a mutated patch of clonal cells develops from a stem cell which
has developed a mutation. Clonal expansion occurs as the mutation confers growth
advantage and the colony escapes normal growth control, thus developing a competitive
advantage. As the clonal expansion continues, normal cells are displaced. Eventually
within the patch, further genetic hits occur creating areas with subclone populations of
cells. This occurs multiple times until eventually, a tumour develops. In addition to head
and neck cancers, field cancerization has been identified in lung, esophageal, vulva,
cervix, colon, breast bladder and skin cancers. This can then be used to explain the
development of second primary tumors, and must be considered post resection as
portions of the patch of clonal cells likely remains in situ (108). Therefore, regardless of
excision of the original lesion, the atypical cells within the area are also at risk of
malignant transformation.
This is supported by Bedi et al who evaluated 8 women who had either synchronous or
metachronous head and neck squamous cell carcinomas. They evaluated genetic
changes, specifically the pattern of X-chromosome inactivation of multiple primary
tumours. The logic was, that if the pattern of X-chromosome inactivation were the same
in the different tumors, then they were likely from the same origin. X-chromosome
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inactivation was used as the marker as this occurs during embryogenesis and is random.
This random deactivation is then passed along to all daughter cells prior to malignant
transformation. In the study, 8 female patients were assessed who had 2 or more
synchronous primary tumours within the oral cavity. Unfortunately only 4 of the cases
were able to be used do to loss of heterozygosity at the androgen receptor, though all 4
had identical patterns of inactivation of the X-chromosome which they felt supported
their argument (109).
1.6 Biomarkers for oral epithelial dysplasia
1.6.1 Introduction
Assessing the molecular and structural changes for malignant transformation in oral
dysplasia is of the utmost importance in secondary prevention. If a lesion can be
identified for its true malignant potential early, than patients can be monitored more
appropriately based on risk. As previously noted, H&E staining and interpretation by
pathologists is subjective, highlighting the importance of other means, as primary or
adjunct methods for identifying these lesions. Markers for oral dysplasia with the
greatest risk of malignant transformation include genomic markers, such as DNA
aneuploidy, chromosome aberrations, and alterations to oncogenes and tumor suppressor
genes such as p53. Proliferation markers, differentiation markers and epigenetics may
also be of some value. A molecular marker that could identify lesions that are truly at
increased risk of malignant transformation as compared to others would be significantly
beneficial. The ideal marker would be easily stained and have sufficiently high sensitivity
and specificity.
(64).
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1.6.2 S100A7 in oral epithelial dysplasia and oral squamous cell carcinoma
The S100 family is comprised of a large number of low molecular weight proteins. The
gene family was first identified in bovine brain tissue, during experimentation to identify
proteins unique to the nervous system. It was named S100 because it was soluble in
100% saturated ammonium sulfate solution (110). Approximately 15-17 S100 protein
genes are present on the epidermal differentiation complex (EDC) on chromosome
1q21(111)(112). These genes are closely related within the complex with other genes that
are responsible for terminal differentiation of keratinocytes. In addition to S100 proteins
these genes encode trichohyalin, profilaggrin, involucrin, SPRR3, SPRR2A, SPRR1B,
and loricrin (113). These genes are part of 3 main gene families that are present in the
EDC, namely Small Proline Rich proteins (SPRR), the Late Cornified Envelope (LCE),
and S100 (111). The effects of the S100 proteins has been seen both intracellularly and
extracellularly (114). The S100 proteins serve as calcium sensor proteins, which once
bound work to upregulate, activate, or alter the subcellular distribution of their target
proteins (115). Structurally, they contain two EF hand calcium binding domains (loophelix-loop). These domains have an N-terminus and a carboxy-terminus, with a hinged
component in between. It is the carboxy terminus that is variable amongst the S100
protein family, and imparts specificity for different targets (116). The monomers are
bound together in an antiparallel fashion, forming dimers within the cells, with or without
calcium bound. However, when calcium is present and bound, a cleft is revealed in each
of the monomers which exposes the functional domain to the target proteins. When the
clefts are bound with their targets, which are at opposite ends due to the antiparallel
orientation, the S100 dimer acts as a connection between the two target proteins (117).
S100A7 is 11.4kDa protein first identified in psoriatic epidermis by Madsen et al in an
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attempt to isolate proteins unique to the skin condition. The upregulation of S100A7
mRNA was determined with immunoblotting and in situ hybridization (118). Expression
of S100A7 within normal epidermis is minimally present but is found within the spinous
and granular layers with very scarce expression in the basal layer. In this study, in which
immunohistochemistry was utilized, both cytoplasmic and nuclear staining were
appreciated (119). Interestingly, another study of both normal and psoriatic plaques and
the expression of S100A7 it was found that S100A7 was expressed in the basal layer and
the spinous layer. In the basal layer, it was found that there was expression in both the
nucleus and the cytoplasm, however, the expression of S100A7 in the spinous layer was
predominantly found at the plasma membrane (120). In the oral cavity, it appears that
typical staining is confined to superficial layers of tissue and is rarely present in the basal
layer (121). Additionally, it was found that the staining of S100A7 within the spinous
layer appears to be cytoplasmic and concentrates at the plasma membrane (120).

Functionally, the S100A7 role within the cell has not been completely defined. It has
been proposed to be involved in keratinocyte differentiation, inflammation and
immunology. With respect to differentiation, S100A7 has been found to be induced when
differentiation was promoted by factors such as high extracellular calcium and loss of
contact with the extracellular matrix (122). It was found that there was essentially no
expression in the undifferentiated cells of the basal layer, and more significantly
expressed in the differentiated layers, carcinoma in situ, and well differentiated SCC.
The expression was proportional to the level of differentiation (122). Unfortunately, the
role that S100A7 plays in the process of differentiation is unknown. Further studies have
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shown that expression of S100A7 may also coincide with regulation of tight junctions via
GSk-3 and MAPK, as well as keratinization proteins such as Beta-Catenin and ECadherin and therefore altering the innate immunity of the keratinocytes (123). The
expression of S100A7 was also investigated along with other defense/immune proteins.
Cell stress such as UV-B light has demonstrated expression of S100A7 in addition to
Beta-defensins-2,-3, and ribonuclease 7 (124). This upregulation in response to cell stress
maybe regulated through cellular expression of Il-22, a cytokine present within
epithelium, produced by NK and Th1 cells (125). While S100A7 appears to have
extracellular function as a CD4+ chemotactic agent, its secretion and mechanism is
unclear (126)(114). Furthermore, expression of interleukin-1 alpha as part of the
inflammatory response occurs via p38, with knockdown of p38 resulting in an absence of
interleukin-1alpha (127).
Identification of S100A7 as a biomarker initially came from the evaluation of tissue from
patients with head and neck squamous cell carcinoma. In an attempt to identify a reliable
biomarker, Ralhan et al, preformed quantitative proteomics on tissue homogenates from
patients with head and neck squamous cell carcinoma. Via isobaric tag for relative and
absolute quantitation (iTRAQ), and verified with western blot, RT-PCR, and
immunohistochemistry, differential expression of proteins between a normal control
group and the cancer group were evaluated. 811 non-redundant proteins were identified.
Of these tests, the 3 best preforming proteins were stratifin (14-3-3 sigma), YWHAZ (143-3 zeta) and S100A7 which were identified as possible biomarkers that were upregulated
in the squamous cell carcinoma group, and not in the control group (128).
With this knowledge, the same group then evaluated tissue homogenates of oral
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dysplastic lesions as well as normal oral mucosa to determine proteins present in
dysplastic tissue that were nonredundant. In total 459 proteins were identified.
Furthermore, they then completed immunoblotting, RT-PCR and immunohistochemistry
to further verify these proteins. Interestingly, S100A7 was not originally identified as a
non-redundant protein, however, given its performance in the head and neck squamous
cell carcinoma trials, S100A7 and prothymosin (PTHA in this study, PTMA in others)
were added to the immunoblotting, RT-PCR and immunohistochemistry with the other
well preforming proteins, stratifin and heterogeneous nuclear ribonucleoprotein K
(hnRNPK). The end result was the identification of 5 biomarkers that were significantly
upregulated in the dysplastic tissue (129).
Following this study, the 5 biomarkers identified as potentially useful were tested using
immunohistochemistry in 110 patients with previously diagnosed dysplasia. This group
of patients were unique to this study, and there was no overlap between this and the
previous two studies. The patients were followed for a mean of 43 months, with a
maximum of 150 months. Of the 110 patients, 39 developed squamous cell carcinoma.
Mean time to transformation was 27 months. The 5 biomarkers were evaluated in those
that transformed and those that did not. While each of the biomarkers were upregulated in
the dysplastic lesions, it was the S100A7 that demonstrated a statistically significant
difference between those that transformed and those that did not with a p-value of 0.014.
They did not find any correlation between grade of dysplasia and overexpression of
S100A7. This led to further evaluation of the S100A7 expression with Kaplan-Meier
survival analysis which demonstrated that lesions with overexpression of S100A7 in the
cytoplasm had a greater reduction in oral cancer free survival when compared to those
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with less cytoplasmic staining (130).
Armed with this information, immunohistochemistry (IHC) with S100A7 staining was
carried out to further assess S100A7 and prognostic utility. In this study, S100A7 IHC
was carried out in normal, squamous hyperplasia, dysplastic and malignant tissue
samples. They found that there was a specificity of 95% for nuclear staining in squamous
hyperplasia, dysplasia and squamous cell carcinoma, and 84% for cytoplasmic staining
(131). Additionally, they found that nuclear staining led to a greater reduction in cancer
free survival as compared to cytoplasmic staining.
1.6.3 Straticyte™
A diagnostic test called Straticyte™, created in Toronto Canada by Proteocyte
Diagnostics Inc., utilizes S100A7 expression within dysplastic tissue samples to establish
a risk of malignant transformation. A proprietary algorithm is utilized to quantify the
expression and create a 5-year cancer risk score. One hundred and fifty (150) oral
epithelial dysplasia tissue samples from patients with known outcomes were collected
then split into 2 groups randomly: 110 into the learning group, 40 into the test group. The
algorithm was recompiled, using the training set. Probability cut offs were established,
with less than 21% indicating low risk of progression, and greater than 55% indication
high risk of progression. 22-54% is intermediate risk. Compared to standard
histopathological assessment, Straticyte™ had improved separation between the 3
groups, with a sensitivity of 95% for low, intermediate and high risk as compared to 75%
for mild, moderate and severe dysplasia (132). Interestingly, S100A7 staining was not
found to be useful in detecting a progression of grade of dysplasia. A recent study from
our lab evaluating S100A7 via manual immunohistochemistry scoring as well as
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Straticyte™, found no significant relationship with respect to S100A7 staining and
predictability of progression of dysplastic lesions from mild to moderate to severe (121).
This seems somewhat counter intuitive as progression of dysplasia would seemingly also
likely predict a progression to squamous cell carcinoma. It may also highlight the low
reliability and subjectivity of traditional grading methods.
1.6.4 S100A7 in other cancers
S100A7 has been identified as a potentially significant biomarker in other cancers as
well. With respect to the bladder carcinoma, one study evaluated the presence of protein
within the urine of patients with bladder carcinomas. While transition cell carcinoma is
the most common bladder cancer, a small subset of patients develop squamous cell
carcinoma. Urine was analyzed in patients post surgically, and it was found that those
with squamous cell carcinoma of the bladder had S100A7 present within the urine
samples. As such, the potential benefit for these patients would be to monitor for
recurrence, utilizing urine S100A7 as a non-invasive modality for monitoring for
recurrence (135).
For ductal carcinoma of the breast, S100A7 mRNA appears to be up-regulated in lesions
that are in-situ as compared to the invasive form of the cancer which does not have
elevated levels of S100A7. Tissue samples were initially obtained from 3 separate cases,
and later confirmed using 32 independent breast tissue specimens (136). Contradicting
this slightly was the study by Al-Haddad et al, in which they evaluated not only ductal
carcinoma, but lobular, mucinous, medullary and tubular cancers in an attempt to
evaluate S100A7 expression. Fifty-seven (57) invasive breast tumors were evaluated. It
was found via RT-PCR and western blotting, that S100A7 is over expressed in more
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aggressive breast tumors regardless of type, and that it was not exclusive to ductal
carcinoma. The thought at the time of the study was that inflammation caused by the
cancer cells may be involved in the upregulation of S100A7, however, further studies
were required (137).
Additionally, a number of proteins within the S100 family studied to assess their
differential expression in esophageal cancer. Sixteen S100 genes were identified, with
primers fabricated. A semi-quantitative assessment via RT-PCR was carried out to
determine the expression of each of the genes. Of the 16 genes, 11 were significantly
down regulated, with only the S100A7 being significantly upregulated, which again
strengthens the argument that S100A7 plays a role in epithelial carcinomas (138). In
keeping with these epithelial findings, Real time RT-PCR was used to evaluate mRNA
levels of IL-8 and S100A7 in precancerous lesions, squamous cell carcinomas and basal
cell carcinomas of the skin. While S100A7 mRNA was upregulated in each of the
lesions, only SCC had increased levels of both IL-8 and S100A7. This would suggest
that S100A7 does play a role in tumourigenesis, and may be independent of inflammation
and differentiation in keratinocyte tumours (139). Lastly, RT-PCR, immunoblotting and
immunohistochemistry were used to evaluate the presence of S100A7 RNA and protein
within different lung tissues, including normal and benign tumour tissue, squamous cell
carcinoma, large cell carcinoma, adenocarcinoma and small cell carcinoma. In addition,
sera from the above tissue samples were also analyzed with ELISA to determine if
S100A7 expression was variable. It was found that S100A7 protein and RNA were
upregulated in SCC, adenosquamous carcinoma and large cell carcinoma, but not in small
cell or adenocarcinoma. Minimal levels were detected in the benign tumours, and none
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was found in normal tissue. The sera of the squamous cell carcinomas demonstrated
elevated levels of S100A7, which could have further diagnostic value as a useful
biomarker (140).
1.7 Mitogen activated protein kinase (MAPK)
In general, there are 3 conventional enzymatic pathways involved in Mammalian MAPK
signalling: Extracellular signal related kinase (ERK), p38, and Jun Kinase (JNK)
pathways (141). These pathways share similar organization with 2 serine/threonine
kinases, and one double specificity threonine/tyrosine kinase. Starting from upstream,
there are at least 3 enzymatic reactions that are activated sequentially, which tend to be
generically named MAPK kinase-kinase (MAPKKK), MAPK kinase (MAPKK), and
MAPK. Each of the intermediate levels phosphorylates the next level down (142). These
enzyme pathways convert extracellular stimuli into a vast number of intracellular
responses as the signal is integrated, relayed, and amplified(143). The activation of these
pathways alters gene expression, division and replication, metabolism, survival apoptosis
and differentiation (141).
The activity of the pathways varies slightly. For the MAPK/ERK pathway, which is also
considered the classical pathway, the downstream effect is dependant not only on the
timing, duration and intensity of the signal, but that spatial localization of the enzyme as
well. As such, this highly regulated cascade can be regulated by extracellular signals
such as growth factors and interactions with other cells, as well as internal signalling
pathways related to DNA damage and internal metabolic stress stimuli. Activation of
these pathways results in cell proliferation, and can be mutated in malignant
processes(142). With binding of the plasma membrane growth factor receptors, the signal
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cascade is initiated resulting in activation of ERK1/2 once phosphorylated. Once
activated, ERKs translocate into the nucleus and alter expression of genes related to
replication and growth (143). The cyclin D1-cdk4/6 complex assembly is regulated posttranscriptionally by activated products of the ERK1/2 pathway, and as such ERK1/2
contributes to regulation and passage of the G1/S check point. This is because cyclincdk4/6 is involved in the phosphorylation of Rb and therefore activation of E2F
transcription factor (143). Additionally, Cdk2 translocation into the nucleus is directly
affected by ERK1/2, and cdk2 is required for activation of cyclinA and cyclinE, which
are also involved in allowing passage of the cell through the G1/S check point, and
progression the S phase (143).
There are multiple isoforms of JNK which are the product of splicing between 3 genes,
Jnk1, Jnk2, Jnk3. While Jnk1 and Jnk2 are expressed throughout the body, Jnk3 has been
found to be expressed in the brain, heart and testis only (144). JNK is known as a stress
activated pathway, and as such, is activated by inflammation, environmental stress,
ionizing radiation, oxidative stress DNA damage, and growth factors (143). Once
activated, JNK phosphorylates a number of transcription factors, including p53, which in
turn bind target genes and either upregulate or downregulate (144). Additionally, they are
involved in metabolism, cell transformation and actin reorganization, and is involved
with insulin inhibition both in inflammatory states, and as a feedback inhibitor during
stimulus states (145).
p38 also plays a role in the inflammatory response and immune response. There are 4
isoforms alpha, beta, delta and gamma. Of these forms, alpha is the most prominent. p38
is present in the cytoplasm and nuclei in quiescent and active cells, phosphorylating
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substrates in both compartments. They may come together in the nuclei when stressors
are present. Extracellular stressors that have been identified as activators of p38 include
UV radiation, hypoxia, ischemia, oxidative stress, inflammatory cytokines, interleukin-1,
and tumor necrosis factor alpha. Many of these stressors also activate the JNK pathway
and many of the enzymes within the activation pathway are shared. The function of p38
is predominantly involved in the production of pro-inflammatory cytokines by
modulating transcription factors or mRNA targets(141). With respect to inflammation
within the epithelium, down regulation of p38 alpha appears to decrease inflammation
and expression of inflammatory genes (146). This is supported by the fact that Il-1 alpha
activation via S100A7 is mitigated through knock down of p38 (147). As such, activity
of p38 appears to be involved in cell cycle inhibition by preventing the expression of
Cyclin D1 and by regulating the passage of the cell through the G1/S check point as its
activity is required for cdc42 arrest (143). It also regulates the cell through mitosis by
arresting the cell at the spindle assembly stage of division(148).
1.8 Digital slide assessment and QuPath
Digital slide assessment has been a point of interest since the 1960s, and has continued to
draw interest with the improvement of technology (149). While originally difficult,
Whole Slide Imaging is now utilized to digitally capture histopathologic specimens in
high resolution, for diagnostic and research laboratories (150). Whole Slide Imaging has
been validated in a number of studies, including a systematic review which indicated with
high quality studies that the use of whole slide imaging was comparable to the use of
light microscopy (151).
The benefit of using virtual slides for digital pathology are numerous as these slides can
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be added to digital charts, utilized as pooled samples from different sites for research, and
allow for cooperation between people in different fields and in different locations to
analyze the same slide (152). Additionally, it allows for extraction of quantitative
information from the sample by allowing measurement of length or area, cell counts such
as mitotic figures, or structure identification and pattern recognition. There is also
potential for improved efficiency and productivity with validated algorithms, which could
improve workflow (150).
For example, Keenan et al found that digital image analysis could be used to accurately
map out nuclear location and crowding within cells in their assessment of cervical
biopsies. They found that the automated computer based assessment was efficient and
able to accurately distinguish CIN 3 from normal tissue in 98% of cases, demonstrating
the possibility of value in computer based assessments (153). This could enhance the
reproducibility of biomarker interpretation, as there is considerable intra- and interlaboratory differences when it comes to assessment, particularly in samples
demonstrating moderate amounts of staining(154).
Interpretation of biomarkers becomes more difficult with tumor heterogeneity and this
can be made more readily interpretable with the assistance of image analysis with the
addition of annotation tools or grids to improve the objective nature of the assessment
(150).
Qupath is an open source software application that is a tile-based whole slide image
viewer. According to its creator, what distinguishes it from other software applications
for whole slide viewing is its object based data model. This means that an object within
the image can be created and manipulated by annotation tools which allow drawing, or
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segmentation commands for the detection of specific cells. Each annotated area can be
grouped and assessed separately or as a whole, allowing for measurement or
classification. Ultimately this allows QuPath to represent relationships between a very
large number of objects across gigapixel images (155).
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CHAPTER 2: HYPOTHESIS AND AIMS
2.1 Hypothesis
S100A7 protein expression is high in oral epithelial lesions which transform
to malignancy.
2.2 Rationale
The early detection and diagnosis of oral squamous cell carcinoma improves patient
outcomes (14). Oral squamous cell carcinomas are often preceded by lesions with
dysplasia present on microscopy. A problem for clinicians is that not all oral epithelial
dysplastic lesions progress to malignancy, and therefore it is difficult to identify which
lesions require close follow up as opposed to those that do not.
Additionally, the diagnosis of oral dysplasia is via microscopic evaluation. Epithelial
dysplasia within the oral cavity is commonly classified as mild, moderate, severe, or
carcinoma in situ. Unfortunately, there is significant inter and intra-observer variability
in evaluation and diagnosis. Therefore, other methods that could assist in the diagnosis of
dysplasia and specifically identify dysplastic lesions at risk of malignant transformation
would be of significant value.
Many biomarkers have been evaluated, with S100A7 showing potential promise as a
useful predictive aid. If there is a statistically significant, identifiable difference in
expression of S100A7 between dysplastic lesions that progress to OSCC, and those that
do not, it could lead to significant real world benefit to patients and practitioners.
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2.3 Aims
1. Determine the level of S100A7 in oral epithelial dysplasia samples that transform to
malignancy and those that do not.
2. Examine the utility of S100A7 immunoreactivity, 2- and 3-tier grading systems, and
the S100A7 based Straticyte™ assay in predicting malignant transformation of oral
dysplasia.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Case selection, review and diagnosis
3.1.1 Case selection
This study was approved by the Office of Human Resources and Ethics at Western
University. REB(#105954).
Formalin fixed paraffin embedded (FFPE) tissue samples and hematoxylin and eosin
(H&E) stained slides were retrieved from the archives of the division of Oral Pathology,
and London Health Sciences Centre, department of Pathology and Laboratory Medicine,
Schulich School of Medicine and Dentistry at Western University. Samples with a
diagnosis of hyperkeratosis, dysplasia and squamous cell carcinoma were collected from
2001 to 2019, searched within the Oral Pathology database. Each tissue sample is
assigned a code based on diagnosis and recorded in a spreadsheet. Each diagnosis
corresponds with a specific numerical code. Cases were retrieved by searching the data
for the relevant code.
Inclusion criteria were: 1) Hyperkeratosis: the tissue sample collected from within the
oral cavity does not demonstrate any dysplasia. Selection of only hyperkeratosis allows
for homogeneity within the control group. 2) Non-progressing dysplasia: two or more
biopsies collected consecutively from the same anatomical site, collected at separate
encounters which shows either the same, lower, or higher grade of dysplasia but did not
progress to oral squamous cell carcinoma (OSCC); or on a single occasion,
demonstrating dysplasia, but with no further progression after 4 year follow up. 3)
Progressing dysplasia, tissue samples collected from the same anatomical site, with an
initial biopsy demonstrating hyperkeratosis, dysplasia, or another epithelial lesion, which
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progressed to squamous cell carcinoma at that same site. If there were multiple biopsies,
the first one demonstrating dysplasia was used.
Tissue samples from the oropharynx were excluded. Cases were also excluded if the first
biopsy collected demonstrated oral squamous cell carcinoma. If there were multiple
biopsies, the first one demonstrating dysplasia was used.
3.1.2 Tissue grading and diagnosis
Using light microscopy, the H&E slides were reviewed by a histopathologist and the
graduate student author to confirm the diagnosis. The H&E assessment was carried out
together initially for calibration, then carried out individually. The diagnosis categories
of the 3-tier grading system for oral epithelial dysplasia include mild, moderate, or severe
dysplasia.
3.1.3 Binary scoring
In addition to the WHO 3-tier (mild, moderate, severe) grading, each biopsy was assigned
either low grade or high grade status using the 2-tier binary grading system. This was
carried out by the pathologist as well as the graduate student author. Both were blinded to
the 3-tier diagnosis. Initially the samples were reviewed together for calibration, then
independently. The 2-tier grading system is based on cellular and architectural features
(Table 3.1), with an established cut off for low grade and high grade classification to be 4
histological and 5 cytosolic features (96).
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Table 3.1: Criteria for identifying and grading oral epithelial dysplasia.
Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia
classification systems: Predictive value, utility, weaknesses and scope for improvement. J
Oral Pathol Med. 2008;37(3):127–33. Also presented as Table 1.2 in Chapter 1.
Architecture
Irregular epithelial stratification
Loss of polarity of basal cells
Basal Cell hyperplasia
Drop-shaped rete ridges
Increased number of mitotic figures
Abnormally superficial mitoses
Premature keratinization in single cells
Keratin pearls within rete ridges

Cytology
Abnormal variation in nuclear size
(anisonucleosis)
Abnormal variation in nuclear shape
(pleomorphism)
Abnormal variation in cell size
(anisocytosis)
Abnormal variation in cell shape
(pleomorphism)
Increased nuclear:cytoplasm ratio
Increased nuclear size
Atypical mitotic figures
Increase number and size of nucleoli
Hyperchromasia

3.1.4 Case organization
Cases were grouped based on inclusion criteria described above, into:
1. Hyperkeratosis/Controls (Controls)
2. Non-progressing dysplasia (Non-progressing)
3. Progressing dysplasia in which oral squamous cell carcinoma developed, (Progressing)
A total of 149 cases from all three groups were originally considered for inclusion. After
review of the biopsies, some cases were excluded based on biopsies obtained from
different locations within the oral cavity, or due to difficulty in obtaining tissue samples.
Consequently, a total of 108 cases were included. 25 hyperkeratosis control samples were
used and compared with 35 non-progressing dysplastic samples, and 48 samples that
progressed to squamous cell carcinoma from the original dysplastic biopsy. The first
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biopsy for each case was identified as the tissue sample of interest for standardization
(Table 3.2).
Table 3.2: Cases retrieved and included in the study
Diagnosis

Total cases
retrieved

Total number of
biopsies all cases

Controls

31

31

Total first biopsies
from included
cases
25

Non-progressing

50

58

35

Progressing

68

106

48

Total

149

195

108

Demographic data was collected from the biopsy referral form. Data collected
included age, gender, location of the biopsy, smoking history, alcohol consumption.
3.2 S100A7
3.2.1 Tissue preparation and staining
Formalin fixed paraffin embedded tissue blocks were placed on an ice bath and allowed
to cool for 20 minutes. The microtome was set to 5µm, and each block was trimmed to
expose a full surface. The fresh surface was then placed back onto the ice bath. The 5
µm tissue sections were cut from the block, then floated onto a 45°C warm water bath. A
positively charged glass slide was used to collect each section.
Once the tissue was on the slide, it was placed into a slide rack which was then placed
into a 37°C incubator for at least 24 hours before removal. Tissue was cut for negative
and positive experimental controls, H&E stain, S100A7 stain, and for MAPK signaling
pathway proteins p38, ERK1/2 and JNK.
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3.2.2 Establishment of optimal staining conditions
A decloaking chamber was used for antigen retrieval. Optimal conditions for antigen
retrieval were established by altering the decloaking chamber settings (112.5°C or
125°C). Buffer solutions were also trialed. One solution contained Tris (Sigma Aldrich,
St. Louis, MO, USA) + EDTA (Sigma Aldrich, St. Louis, MO, USA) + Tween20 (Sigma
Aldrich, St. Louis, MO, USA), was compared to a buffer solution containing just
Tris+EDTA. It was determined that the best antigen retrieval occurred with the
decloaking chamber set to 112.5°C with a buffer solution of Tris+EDTA+Tween20, pH
9.
3.2.3 S100A7 immunohistochemistry
Using the tissue slides prepared above, S100A7 immunohistochemistry was completed
using the same protocol for each round of tissue staining. The rehydration sequence
began by placing the slides in 100% xylene three times (5:5:3 minutes), then into 100%
ethanol two times (2:1 minutes), 95% ethanol two times (2:1 minutes), 70% ethanol once
(2 minutes), and finally distilled water (dH2O for 2 minutes). The tissue was then placed
into Tris-EDTA buffer, pH 9, with 0.05% Tween 20 in a decloaking chamber. The
chamber was set to reach 112.5°C for 90 seconds then cooled to 90°C for 10 seconds.
The slide racks were then cooled with indirect cold tap water. The slides were placed in a
humidified chamber and washed with Tris Buffered Saline-0.01% Triton X (TBS-T) on
the shaker three times, for three minutes each time. Once washed, the slides were
blocked with 125µl of MACH 4 background punisher (Inter Medico, Markham, ON,
Canada, Catalogue number: BC-BP974L) per slide, for 15 minutes. This is done to
reduce non-specific background staining.
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100 µL of anti-S100A7 (Psoriasin) mouse monoclonal antibody (IgG 1Kappa) (Novus
Biologicals Canada, Oakville, ON, Canada, Catalogue number: NB 100-56559; clone:
47C1068)), diluted to 1:2000 with 1.5% horse serum (VWR International, Toronto, ON,
Canada, Catalogue number: 10015-630) in Tris Buffered Saline (TBS), was added to
each slide. The negative controls received 100 µL of 1.5% horse serum only. These were
then incubated at room temperature for one hour. Once the incubation was complete, the
slides were again washed with TBS-T then placed on the shaker three times for 3
minutes. After the wash, 3% H2O2 in TBS was applied to the slides for 10 minutes to
block endogenous peroxidase activity, then washed again with TBS-T once for three
minutes.
After the wash, 125µl MACH 4 Mouse Probe (Inter Medico, Markham, ON, Canada,
Catalogue number: BC-M4U534L) was added to each slide and incubated for 15 minutes.
Once complete, the slides were washed three times, for three minutes each time, in TBST on the shaker. Next, 125µl MACH 4 HRP (horseradish peroxidase) Polymer (Inter
Medico, Markham, ON, Canada, Catalogue number: BC-M4U534L) was added to each
slide. These were then allowed to incubate for 15 minutes. After the incubation, the
slides were rinsed with TBS-T and placed on the shaker for five minutes, three times.
100 µL of DAB (3,3′-Diaminobenzidine) (MJS BioLynx Inc., Brockville, ON, Canada,
Catalogue number: VECTSK4100) was then added to react with the HRP and develop
the slides. The DAB was left on the slides for no more than five minutes to avoid
excessive background staining. DAB was made fresh and used immediately each time the
staining protocol was completed. The DAB was prepared with 5 ml of dH2O, 2 drops

57
(~84µl) buffer, 4 drops (~100µl) DAB and 2 drops (~80 µl) of H2O2. This was
thoroughly mixed prior to use.
Once the DAB/HRP reaction was complete, slides were rested for up to 5 minutes, then
rinsed in dH2O and counterstained with Harris haematoxylin (Leica Biosystems Inc.,
Concord, ON, Canada) for one minute before being rinsed under tap water. The slides
were differentiated in 1% acid alcohol (HCl/70% Ethanol) before washing them again
with running tap water. The sections were blued in 2% ammonium hydroxide/70%
ethanol, and again, the slides were washed in water.
Dehydration of the slides was then carried out in the following manner: the slides were
placed in 70% Ethanol for one minute, 95% Ethanol for one minute twice, 100% Ethanol
for one minute three times, and finally Xylene for five minutes twice. Cover slips were
applied to the slides utilizing Cytosealä mounting medium (ThermoScientific, Runcorn
Cheshire, WA, USA). The slides were then left to dry, lying flat for at least 24 hours.
3.2.4 Staining controls
With each round of S100A7 staining, a known high risk (dysplasia with high level of
S100A7 protein staining) and low risk (dysplasia with low level of S100A7 protein
staining) tissue samples were included. Positive (S100A7 stained) and negative (primary
antibody omitted) were included (Figure 3.1). Information pertaining to Straticyteä risk
stratification can be found in the section labelled, Straticyteä: Establishing Risk Groups.
Figure 3.1 Staining controls: Representative high and low risk S100A7
(magnification x100). A) High risk S100A7 staining with antibody and B) no
antibody. C) Low risk S100A7 staining with antibody and D) no antibody.
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3.2.5 Microscopic evaluation of S100A7 manual scoring
The immunohistochemistry was analyzed manually via light microscopy. Quantitatively,
the scoring was based on both intensity (0-3), and percentage of cells stained (0-5). The
sum of this number was then tabulated and a score out of 8 was calculated creating the
manual score (Tables 3.3 and 3.4). When evaluating the slides, the epithelium was
scanned and then scored based on a representative portion of the tissue. The intensity
score was based on the overall impression of the cells stained as compared to our high
risk control tissue sample that was included in each run of the staining protocol, while the
percent of cells stained was determined by evaluating the epithelial layer in full. This
takes into account areas of intense staining as well as other areas of mild or no staining.
Qualitatively, the layers within the epithelium were also assessed for the location of the
staining. The epithelium was divided into the following layers: corneum, granular,
spinous, parabasal and basal layers. Additionally, the distribution of the staining was also
noted, as either focal or diffuse, as staining may be minimal, but across the entire
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specimen, or it can be full thickness but only within a small portion of the sample. The
presence of staining and the relative amount of staining within each layer was also
recorded.
Table 3.3: Intensity scores of S100A7 staining via light microscopic evaluation
Score

Intensity

0

None

1

Mild

2

Moderate

3

Intense

Table 3.4: Proportion score for S100A7 staining via light microscopic evaluation
Score
1

Percent cells stained
(%)
1-20

2

21-40

3

41-60

4

61-80

5

81-100

The assessment was conducted by a histopathologist and the graduate student author.
Calibration was carried out prior to scoring, using random tissue samples to reach
consensus. Once all tissue samples were evaluated and scored, 10 random samples were
evaluated by both evaluators to confirm that calibration was maintained. Differences on
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the intensity and percentage scores of greater than 1, were discussed and consensus was
determined.
3.3 Straticyte™ assessment and risk determination
3.3.1 Image and risk analysis
The tissue samples were sent to Toronto for qualitative analysis via Straticyteä. Using
the Hamamatsu Nanozoomer-XR slide scanner (Toronto Centre for Phenogenomics,
Toronto, Ontario, Canada) the slides were digitally scanned and imported into
Visiopharm VIS (Hoersholm, Denmark). Up to five regions of interest (ROIs) were
identified within the epithelial layers in areas of high S100A7 staining. These regions had
500 μm diameters. The positive S100A7 and average cell size were calculated and used
to generate the Straticyteä risk category and probability of cancer progression scores.
The risk category was determined based on the percent chance of progression to cancer
(Table 3.5).
Table 3.5: Straticyte™ 5-year probability of malignant transformation and risk
category
Risk category
Low

Percent probability of
malignant transformation
(%)
<19

Medium

20-59

High

>60

Figure 3.2 provides an example of the Straticyte™ assessment. The green outline of the
specimen simply identifies the tissue, while the teal area is S100A7 staining. The green
dots outside of the ROI represent S100A7 negative nuclei. The blue line outlines the
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specific ROIs within the tissue sample. Within the ROI, maroon represents the areas with
S100A7 staining, while the red areas are S100A7 negative. The light purple areas are
representations of the background glass in areas of tissue porosity. Within the ROI, the
green dots indicate S100A7 negative nuclei, while the blue ones are positive. With this
tissue sample, the Straticyte™ Risk was medium, with a 5-year malignant transformation
risk of 31%.
Figure 3.2: Straticyte™ image analysis. Control from the gingiva with detail
containing ROI in red. Image provided by Dr. Jason Hwang, Proteocyte AI,
Toronto, ON, Canada

3.4 QuPath image analysis
As an additional method of evaluating the tissue slides, an open source software,
QuPath™ (https://qupath.github.io) was used for objective measurements. Ten tissue
samples were selected consecutively. Tissues with folds were excluded. These were sent
for Whole Image Scanning using an Aperio scanner (Leica Biosystems Inc, Wetzler
Hesse, Germany). Utilizing one of the QuPath annotation tools, the total area of the
epithelium, as well as the total area of stained cells was calculated. From this, “Percent
Cells Stained score” (area of stained cells/ area of total epithelium) was calculated. A raw
area was obtained and documented. As with the manual S100A7 scoring, demonstrated in
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Tables 3.3 and 3.4, this was converted to a score out of five, and added to the intensity
score out of three to create a total QuPath score, as was done for the manual scoring.
3.5 Mitogen-Activated Protein Kinase staining
Consecutive tissue samples from the three populations; Hyperkeratosis/Controls, Nonprogressing dysplasia, and Progressing to OSCC, were selected for further
immunohistochemistry for three Mitogen-activated protein kinase (MAPK) proteins: p38,
Erk1/2, and JNK. A total of 30 tissue samples, ten from each population, were stained.
Our positive control for each of these staining protocols was an oral squamous cell
carcinoma (OSCC), the same used for the S100A7 staining protocols.
3.5.1 p38: immunohistochemistry protocol
Slides were initially immersed in xylene solution twice, for five then three minutes. This
was done in two different containers. Absolute alcohol was next for two minutes then
95% alcohol for two minutes, 95% alcohol for one minute, then 70% alcohol for one
minute. They were then placed in water for two minutes.
To quench the tissue, the slides were placed in fresh 3% hydrogen peroxide in methanol
for five minutes (prepared from 30% H2O2) (20 ml 30% H2O2 and 180 ml Methanol).
Once this step was complete, distilled water was used to rinse the slides for five minutes,
and then a five minute Phosphate buffered saline (PBS) rinse was completed on the
shaker.
Antigen retrieval was completed in citrate buffer, pH 6.0 in a de-cloaking chamber. Once
again the slides were rinsed with running tap water, then PBS for 5 minutes each. For
blocking, 2.5% horse serum was utilized, and the slides were incubated for 30 minutes at
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room temperature in a humidified chamber. After 30 minutes, the 2.5% horse serum was
drained onto a paper towel. The slides were then incubated with p38 (P38 MAPK
(Tyr323) Rabbit polyclonal, BS5477R, Cedarlane Laboratories, Burlington, ON) at a
1/200 dilution, which was determined by preliminary titrations. Incubation then took
place overnight.
The following day, the slides were rinsed with PBS for five minutes on the shaker then
incubated with Rabbit ImmPres kit (horse-radish peroxidase micro-polymer solution)(
Vectastain Elite ABC- Peroxidase kit, rabbit, VECTPK6101 MJS Biolynx, Inc.) for 30
minutes at room temperature. They were rinsed twice for five minutes with PBS on the
shaker. While the samples were rinsing, DAB was prepared as follows: two drops of
buffer, with four drops of DAB and two drops of H2O2 were added to 5ml of dH2O, in
that order. The solution was placed on the vortex between each addition. Then one to
two drops of DAB are added to each slide, and then incubated for 10 minutes. The DAB
was then rinsed with water into the waste container.
Harris Hematoxylin counterstaining was then completed, with the slides staining for one
minute, before being rinsed with running tap water. Slides were dipped 1-2 times in Acid
Alcohol (1% Hydrochloric Acid in 70% Alcohol), then rinsed again with running tap
water. Slides were then blued in 2% ammonium alcohol and rinsed in running tap water.
The process continued with the following reagents: 70% alcohol for one minute, 95%
alcohol for one minute two times, absolute alcohol for two minutes then one minute, then
xylene for five minutes and 3 minutes. Cover slips were then placed with Cytoseal®
permount in the fume hood.
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3.5.2 ERK 1/2: immunohistochemistry protocol
Tissue sections were initially immersed in xylene solution twice, for five then three
minutes. Absolute alcohol was next for two minutes then 95% alcohol for two minutes
then one minute, then 70% alcohol for one minute. They were then placed in water for
two minutes.
To quench the slides, they were placed in fresh 3% hydrogen peroxide in methanol for
five minutes (20 ml 30% H2O2 and 180 ml Methanol). Once this step was complete,
distilled water was used to rinse the slides for five minutes, and then PBS was further
utilized for another five minute wash on the shaker.
For the ERK1/2 protocol, antigen retrieval was not necessary. The tissue was blocked
with 2.5% horse serum for 30 minutes at room temperature. The blocking serum was
then drained. There was no PBS rinse. The slides were then incubated with ERK 1/2
(ERK1+ERK2 (T185+Y187+T202+Y204) Rabbit polyclonal, BS5469R, Cedarlane
Laboratories, Burlington, ON) at a 1/400 dilution. This dilution was determined with
preliminary titrations. The slides were incubated at 4ºC overnight in a humidified
chamber.
The following morning the slides were rinsed with PBS for five minutes on the shaker.
Once complete, they were incubated at room temperature for 30 minutes with the Rabbit
Impress kit (horse-radish peroxidase micro-polymer solution). Again, the slides were
rinsed on the shaker with PBS for five minutes. While the samples were rinsing, DAB
was prepared as follows: two drops of buffer, with four drops of DAB and two drops of
H2O2 were added to 5ml of dH2O, in that order. The solution was placed on the vortex
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between each addition. Then one to two drops of DAB are added to each slide, and then
incubated for 10 minutes. The DAB was then rinsed with water into the waste container.
Harris Hematoxylin counterstaining was then completed, with the slides staining for one
minute, before being rinsed with running tap water. Slides were dipped 1-2 times in Acid
Alcohol (1% Hydrochloric Acid in 70% Alcohol), then rinsed again with running tap
water. The sections were blues in 2% ammonium alcohol and rinsed with running tap
water.
The process continued with the following reagents: 70% alcohol for one minute, 95%
alcohol for one minute two times, absolute alcohol for two minutes then one minute, then
xylene for five minutes and 3 minutes. Cover slips were then placed with Cytoseal®
permount in the fume hood.
3.5.3 JNK: immunohistochemistry protocol
Tissue sections were initially immersed in xylene solution twice, for five then three
minutes. Absolute alcohol was next for two minutes then 95% alcohol for two minutes
then one minute, then 70% alcohol for one minute. They were then placed in water for
two minutes. The slides were placed in a humidified chamber and rinsed with TBS-T for
5 minutes. For blocking, 2.5% horse serum (made in TBS) was utilized, and the slides
were incubated for 30 minutes at room temperature. The blocking serum was then
drained onto a paper towel, no rinsing, and then incubated with JNK (PhosphoSAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb, 46685, New England Biolabs,
Whitby, ON) at 4ºC overnight in a humidified chamber.

66
The following morning, the slides were rinsed with TBS-T for five minutes on the shaker,
then quenched for five minutes using a solution of 9ml TBS, and 1ml H2O2. The
secondary rabbit biotinylated antibody (Vectastain elite ABC- Peroxidase kit, rabbit IgG
as VECTPK6101 MJS Biolynx Inc) was prepared to a dilution of 1/200 in 2.5% horse
serum, then slides were incubated for 30 minutes at room temperature. After this, sections
were rinsed twice with TBS-T for five minutes each time, on the shaker. The tissue was
then incubated with ABC reagent for 30 minutes at room temperature. Again, this was
rinsed twice with TBS-T on the shaker for five minutes. While the samples were rinsing,
DAB was prepared as follows: two drops of buffer, with four drops of DAB and two
drops of H2O2 were added to 5ml of dH2O, in that order. The solution was placed on the
vortex between each addition. Then one to two drops of DAB are added to each slide,
and then incubated for 10 minutes. The DAB was then rinsed with water into the waste
container.
Harris Hematoxylin counterstaining was then completed, with the slides staining for one
minute, before being rinsed with running tap water. Slides were dipped 1-2 times in Acid
Alcohol (1% Hydrochloric Acid in 70% Alcohol), then rinsed again with running tap
water. Slides were blued in 2% Ammonium Alcohol.
The process continued with the following reagents: 70% alcohol for one minute, 95%
alcohol for one minute two times, absolute alcohol for two minutes then one minute, then
xylene for five minutes and 3 minutes. Cover slips were then placed with Cytoseal®
permount in the fume hood.
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3.5.4 Microscopic evaluation of MAPK stained tissue
The immunohistochemistry was analyzed manually via microscopy. Quantitatively, the
scoring was based on both intensity, 0-3, and percentage of cells stained, 0-5. The sum of
this number was then tabulated and a score out of 8 was calculated, just as it was for the
S100A7 staining. The scoring scale is represented in Tables 3.3 and 3.4. When
evaluating the slides, the epithelium was scanned and then scored based on a
representative portion of the tissue. The intensity score was based on stained visualized
average of the lightness or darkness of staining using the OSCC positive control as a
reference, while the percent of cells stained was determined by estimating the number of
cells stained in the entire epithelial layer.
Epithelial layers were also assessed for the location of the staining. The epithelium was
divided into Corneal, Granular, Spinous, Parabasal and Basal layers. The presence of
staining and the relative amount of staining within each layer was recorded, as was the
presence of stain within the nucleus or cytoplasm.
The assessment was conducted by a histopathologist and the graduate student author.
Calibration was carried out prior to scoring when random tissue samples were selected
and consensus was reached. Once all tissue samples were evaluated and scored, ten
random samples were evaluated by both evaluators to confirm that calibration was
maintained. Differences on the intensity and percentage scores of greater than 1, were
discussed and consensus was determined.
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3.6 Statistical methods
Statistical analysis was caried out using SPSS® (IBM®, Armonk, NY, USA) with the
level of significance being set at P ≤ 0.05. For initial assessment of the each of the
grading and assessment methods, an ANOVA was used to establish if a statistically
significant difference existed between the populations. To further characterize
differences between populations, a Tukey Multiple comparison was performed for each
of the grading and assessment methods. This allowed for more specific data, identifying
between which populations differences existed, and whether these were statistically
significant for each of the assessment methods.
For correlational information, Pearson Correlation Coefficients were calculated.
Information gathered allowed for identification of correlational relationships between
grading and assessment methods for each of the study populations. Statistical analysis
was carried out twice: One set of data was from all populations and assessment methods
excluding QuPath. The second statistical assessment included a subset of each of the
populations, 10 tissue samples from each of the groups, and included QuPath assessment.
This was set as a pilot study to assess the feasibility of QuPath S00A7 assessment and
determine if a more accurate S100A7 score can be obtained to improve its utility in
differentiating the populations.
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CHAPTER 4: RESULTS
4.1 Results
4.1.1 Patient Demographics
One hundred and eight tissue samples were selected for the study: 25 within the
Hyperkeratosis/Control (Control) group, 35 within the Non-progressing Dysplasia (Nonprogressing) group, and 48 from the Progressing to OSCC (Progressing) group. The age
at initial biopsy for each of the groups ranged from: 15-72 years (avg. 50.4 years) for the
Control group; 31-74 years (avg. 55.4 years) for the Non- progressing group, and 40-86
years (avg. 62.2 years) for the Progressing group was (Figure 4.1).
In the Control group, there were 13 males and 12 females. The average age was 46.9 for
males, and 54.1 for females. Within the Non- progressing group, there were 18 males and
17 females. The average age was 57.4 years for males and 50.6 years for females. In the
Progressing group there were 25 males, and 23 females with average ages 61.0 years for
males and 63.3 years for females. (Tables 4.1 - 4.3).

Age of patient at initial
biopsy (years)

Figure 4.1: Average age of patients at initial biopsy from each of the three study
populations: Control, Non-progressing, and Progressing
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Table 4.1: Control population gender and average age at first biopsy
Gender

Count
(%)

Average age
in years

Male
Female

13 (52)
12 (48)

46.9
54.1

Table 4.2: Non-progressing dysplasia population gender and average age at first
biopsy
Gender

Count
(%)

Average age
in years

Male
Female

18 (51)
17 (49)

57.4
50.6

Table 4.3: Progressing population gender and average age in years at first biopsy
Gender

Count
(%)

Average age
in years

Male
Female

25 (52)
23 (48)

61.0
63.3

Other demographic information collected included tobacco and alcohol use. Many of the
clinical information forms and biopsy reports made no mention of either of these two risk
factors. For the Control group, 10/25 had known tobacco histories, with 7/10 having used
tobacco while three had not. Alcohol consumption was not recorded on the clinical
information forms for any of the control group. For the Non-progressing group, 23/35
biopsy reports included the patient tobacco history. 21/23 used tobacco, while two did
not. 5/35 patients had known alcohol statuses with 4/5 having a history of alcohol
consumption, and one reporting no use. In the Progressing group, 15/48 biopsy reports
had information regarding tobacco with 12/15 reporting positive histories of tobacco use,
while three reported no tobacco use. Only 2/48 alcohol histories were known, with both
consuming alcohol. Given the significant deficiency in data with respect to tobacco and
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alcohol status, there was insufficient data to complete further statistical analysis, though
of known cases, it would appear that tobacco and alcohol use contribute to lesions which
result in biopsy.
4.1.2 Lesion Location
The most common sites involved were the lateral tongue, ventral tongue and floor of
mouth (FOM). 16 lateral tongue lesions, and 12 ventral tongue/FOM lesions progressed
to OSCC. Lesion located on the buccal mucosa and lip were most prevalent in the
Progressing group with six of each while the Non-progressing and Control groups did not
have any biopsies from these sites. The dorsal tongue was the least biopsied site from the
oral cavity, with one biopsy demonstrating hyperkeratosis. A breakdown of all lesion
locations is present in Table 4.4.
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Table 4.4: Location of lesion within the oral cavity for each of the three study
populations
Location

Ventral
tongue/FOM
Lateral
tongue
Soft palate
Hard palate
Gingiva
Retromolar
trigone
Dorsal
tongue
Buccal
Mucosa
Lip
Total

Control

Non- progressing

Progressing

n

%

n

%

n

%

5

20

17

49

12

25

11

44

11

31

16

33

1
2
2
3

4
8
8
12

5
0
1
1

14
0
3
3

2
2
4
0

4
4
8
0

1

4

0

0

0

0

0

0

0

0

6

13

0
25

0
100

0
35

0
100

6
48

13
100

4.1.3 Diagnosis
The diagnosis for each of the initial biopsies is presented in tables 4.5-4.9. The NonProgressing and Progressing groups included not only dysplasia, but squamous
architectural atypia, hyperkeratosis, actinic cheilitis, lichenoid mucositis, verrucous
hyperplasia, hyperplastic candidiasis, and traumatic ulcerative granuloma with stromal
eosinophilia (TUGSE). For each of the initial biopsies with dysplasia the 3-tier diagnosis
as well as the 2-tier diagnosis were recorded.
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Table 4.5: Control group diagnoses
Diagnosis

Cases (%)

Hyperkeratosis

25 (100%)

Table 4.6: Non-progressing group diagnoses including the 3-tier dysplasia diagnosis
Diagnosis

Cases (%)

Hyperkeratosis
Mild
Moderate
Severe
Total

4 (11%)
23 (66%)
8 (23%)
0 (0%)
35 (100%)

The 3-tier diagnoses of the Non-progressing population is present in Table 6. The
dominant diagnosis within this group is mild, representing 66% of the initial biopsies.
Table 4.7: 2-tier diagnoses for the Non-progressing group
Diagnosis

Cases (%)

Low
High
Total

27 (77%)
8 (23%)
35 (100%)

The 2-tier diagnoses of the Non-progressing group is presented in table 7. Low grade
dysplasia was the dominant diagnosis with 77% of all cases.
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Table 4.8: Progressing group diagnoses including the 3-tier dysplasia diagnosis
Diagnosis

Cases (%)

Atypia/Hyperkeratosis
Mild
Moderate
Severe
Actinic cheilitis
Other
Total

8 (17%)
11 (23%)
13 (27%)
5 (10%)
3 (6%)
8 (17%)
48 (100%)

Table 4.8 contains the 3-tier diagnoses for the sample population Progressing to OSCC.
“Other” diagnoses included lichenoid mucositis, verrucous hyperplasia, hyperplastic
candidiasis and traumatic ulcerative granuloma with stromal eosinophilia (TUGSE). The
most common diagnosis was moderate dysplasia, (27%) followed by mild (23%).
Table 4.9: Progressing group diagnoses including the 2-tier dysplasia diagnosis
Diagnosis

Cases (%)

Low grade
High Grade
Other
Total

10 (21%)
33 (69%)
5 (10%)
48 (100%)

When each initial biopsy for the Progressing to OSCC group was graded utilizing the 2tier system, 33 (69%) of the tissue samples were considered high grade dysplasia. Low
grade lesions were diagnosed in 10 (21%) cases (table 4.9). Five of the lesions including
those with squamous or architectural atypia and TUGSE were considered dysplastic
when applying the 2-tier grading criteria. Lichenoid mucositis, hyperplastic candidiasis,
granulation tissue and actinic cheilitis were present in five cases and were classified as
such after 2-tier grading (table 4.9: Other).
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4.2 Immunohistochemistry
Tissue staining from each of the sample populations is presented in the following figures
(4.2- 4.4). For each of the tissue samples presented, the 3-tier, 2-tier, S100A7 manual
score, Straticyte™ assessment and QuPath assessment was completed.
4.2.1 S100A7 qualitative evaluation of staining
Immunoreactivity for S100A7 was present in both the cytoplasm and nucleus, though it
was more prominent within the cytoplasm. Within the three study populations, staining
varied from minimum intensity to heavy. Staining was present in the more superficial
layers of the tissue with the basal layer often spared. Stain trapped within the outer
keratin layer did occur relatively frequently, interpreted to represent artifact
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4.2.2 Control group
Figure 4.2: Case 6: Hyperkeratosis, from gingiva. A) H&E stain (x100
magnification), B) S100A7 Stain (x100 magnification), C) QuPath total epithelial
area, D) QuPath S100A7 total area, E) Straticyte™ ROI analysis, F) Straticyte™.

Figure 4.2 shows tissue from the control group, collected from gingiva. The diagnosis
was determined based on the H&E slide, with an obvious band of orthokeratin overlying
the epithelium (Figure 4.2A). The S100A7 staining is represented in figure 4.2B, and in
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this specimen, the manual score was 7 with an intensity score of 3, and a proportion score
of 4 which equates to 61-80 percent of cells stained. It can be seen that the S100A7
staining appears to be confined to the upper layers of the mucosa, with only incidental
staining within the keratin layer, and no staining in the basal or parabasal layers. Nuclear
and cytoplasmic staining can be appreciated. The QuPath staining is depicted in figure
4.2C demonstrating total epithelial area, and figure 4.2D demonstrating total S100A7
area. The Overall QuPath Score was 7 with an intensity score of 3, and a proportion score
of 4, matching that of the Manual Score. Figure 4.2F shows the Straticyte™ analysis of
the tissue with figure 4.2E providing an enhanced magnification view of a ROI. For this
tissue sample, the Straticyte™ Risk was medium, with a 5-year malignant transformation
risk of 31%.
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4.2.3 Non-progressing dysplasia
Figure 4.3: Case 9: Moderate/High grade dysplasia, from soft palate. A) H&E stain
(x100 magnification), B) S100A7 stain (x100 magnification), C) QuPath total
epithelial area D) QuPath total S100A7 area E) Straticyte™ analysis, F) Straticyte™
ROI analysis.

The tissue shown in figure 4.3 is from the soft palate. The initial 3-tier diagnosis was
moderate dysplasia with a 2-tier diagnosis of high-grade dysplasia from the H&E stain
(Figure 4.3A). S100A7 staining is shown in figure 4.3B. The staining spares the basal and
parabasal areas, and both nuclear and cytoplasmic staining are depicted. The manual
score for this specimen was 4, with an intensity score of 2 and a proportion score of 2.
When QuPath was used to assess the tissue sample the proportion score was based on the
total area (Figure 4.3C) and S100A7 area (Figure 4.3D) and was determined to be 1, with
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an intensity score of 2 resulting in a QuPath Score of 3. Straticyte™ analysis is shown in
figure 4.3E and F with a risk score of medium, and a 5-year malignant transformation
risk of 45%.
4.2.4 Progressing to OSCC
Figure 4.4: Case 4: Mild/Low grade dysplasia, from lateral tongue. A) H&E stain
(x100 magnification), B) S100A7 stain (x100 magnification), C) QuPath total
epithelial and S100A7 area, D) Straticyte™ analysis, E) Straticyte™ ROI analysis

The tissue sample in figure 4.4 is mild dysplasia from the lateral tongue. The 2-tier
diagnosis was low grade dysplasia (Figure 4.4A). The S100A7 manual score was the
maximum score of 8, (based on an intensity score of 3, and a proportion score of 5)
(Figure 4.4B). The QuPath™ score was 8 given that the total area of the S100A7 is equal
to that of the epithelium (Figure 4.4C). Incidental staining of the orthokeratin layer is
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present while there does appear to be faint staining on the basal layer. All other layers of
the tissue were evenly stained. Cytoplasmic and nuclear S100A7 staining was present.
The Straticyte™ analysis in figure 4.4D and E also demonstrate significant S100A7
staining both inside and outside of the ROI. In this case, the Straticyte™ Risk was high
with a 5-year malignant transformation risk calculated to be 69%. Malignant
transformation occurred 13 years later.
4.3 S100A7 staining
Results for S100A7 manual scoring are presented in a dot plot (Figure 4.5), and the bar
graph represented by figure 4.6 and 4.7. Results for Straticyte™ and the associated risk
predictions are presented in tables 4.10-4.12 as well as figures 4.8-4.10. In addition, the
QuPath area calculations are provided to demonstrate the capability of QuPath for
allowing the user to obtain very specific measurements (Tables 4.13-4.15)(Figures 4.114.12). QuPath scores (Figures 4.13-4.15) are present for each of the tissue samples
selected. The QuPath score is an intensity and proportion score similar to that of the
S100A7 manual score, however, QuPath is utilized to obtain the proportion score. The
S100A7 manual scores for the subpopulation of QuPath sampled tissue has also been
presented to demonstrate the difference between the two (Figures 4.16 -4.18).
4.3.1 S100A7 manual score assessment
The dot plot for the S100A7 manual scoring for each of the populations is present in
figure 4.5. The range was from 2-8 for each of the groups, though there is a general trend
toward greater total scores in the Progressing to OSCC group. The median score for the
Progressing, Non-progressing and Control groups were 6, 5 and 4 respectively. Average
manual scores were calculated, and the Progressing population had the highest average
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S100A7 manual score. The average S100A7 manual score for both the Non-progressing
dysplasia and Progressing dysplasia groups was greater than the Control group (Figure
4.6). Median scores were also calculated which were also greatest in the Progressing
group (Figure 4.7)
Figure 4.5: Dot plot for S100A7 manual scores for each of the three populations
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Figure 4.6 Average S100A7 manual score for all three populations calculated from
the intensity and proportion scores
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Figure 4.7: Median S100A7 manual scores for the Control, Non-progressing and
Progressing populations calculated from the intensity and proportion score
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4.3.2 Straticyte: S100A7 risk score
The S100A7 staining of the Control group was evaluated utilizing the Straticyte™ test.
Eighteen (18) of the 25 samples were considered medium risk, which was the most
frequent risk stratification in this population. One of the tissue samples was considered
high risk. (Table 4.10)
Table 4.10: Straticyte™ 5-year risk for malignant transformation: Control group
case numbers
Risk
Low
Medium
High
Total

Count
6
18
1
25

The Straticyte™ score for the initial biopsies for the Non-progressing group were
considered medium risk in 27 of 35 cases, were low risk in 7 and high risk in 1 case.
(Table 4.11). Of the seven low risk group of tissue samples, one was moderate dysplasia,
while six were mild dysplasia. All seven were low grade in the 2-tier grading system.
For the 27 tissue samples that were considered medium risk by Straticyte™, seven were
moderate dysplasia, 16 were mild dysplasia, and four were hyperkeratosis. With respect
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to the 2-tier grading system, eight were high grade, and 19 were low grade. The lone high
risk tissue sample was mild dysplasia, and considered low grade in the 2-tier system.
Table 4.11: Straticyte™ 5-year risk for malignant transformation: Non-progressing
group case numbers
Risk
Low
Medium
High
Total

Count
7
27
1
35

S100A7 staining for the Progressing to OSCC group was evaluated with Straticyte™.
Twenty-two (22) cases were medium risk, and 22 were high risk. None of the tissue
samples were low risk (Table 4.12). If tissue folds were present in the samples, the
Straticyte™ test could not be applied, and was recorded as “unable to assess”, occurring
in four cases. In the high risk tissue samples, five cases were mild dysplasia, five were
moderate, four were severe, five were hyperkeratosis/architectural atypia, two were
verrucous hyperplasia, and one was hyperplastic candidiasis. In the 2-tier system, five
were low grade, 16 were high grade, and one was considered not dysplastic with a
diagnosis of hyperplastic candidiasis. The Straticyte™ medium risk samples were found
to have five mild dysplasia, eight moderate, one severe, one TUGSE, one actinic cheilitis,
three hyperkeratosis, two lichenoid mucositis, and one verrucous hyperplasia. When
evaluated with the 2-tier system, five were low grade, 15 were high grade, and two were
not considered dysplastic and maintained the diagnosis of lichenoid mucocitis.
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Table 4.12: Straticyte™ 5-year risk for malignant transformation: Progressing
group case numbers
Risk
Low
Medium
High
Unable to assess*
Total 48

Count
0
22
22
4

“Unable to assess” tissue samples that had a tissue fold or “bad sections” which
prevented the Straticyte™ assessment.
Figure 4.8.: Dot plot for calculated Straticyte™ 5 year risk score for each of the
three populations
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The dot plot (Figure 4.8) shows the Straticyte™ risk percentage in the study populations.
This demonstrates a trend of increasing risk from Controls, to Non-Progressing, to
Progressing, with more of the tissue samples falling in the 50-80% range in the
Progressing group as compared to the other two populations. The range for the Controls
group is from <10 to 60%. The Non-progressing population had a majority of tissue
samples within the 10% to 50% range. The range for the tissue samples is from 20% to
80% for the Progressing group, the majority are within 50%-80%. Averages for each
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population are present in figure 4.9, and are 31, 37 and 58.7 for the Control, Nonprogressing and Progressing groups respectively. The median scores are 30, 39 and 63
respectively (Figure 4.10). These parameters demonstrate a significant difference
between the Progressing group and the other two populations.
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Figure 4.9: Average Straticyte™ 5 year risk score for malignant transformation
70
60
50
40
30
20
10
0

58.7
37

31

Control

Non-progressing

Progressing

Populations

5 year risk score for
malignant transformation
(%)

Figure 4.10: Median Straticyte™ 5 year risk score for malignant transformation
70

63

60
50
40
30

39
30

20
10
0
Control

Non-progressing

Progressing

Populations

4.3.3 QuPath Assessment of S100A7 staining
Data collected from QuPath include the area of the epithelium, the area of the epithelium
stained by S100A7, percent area stained, and finally a conversion of the QuPath staining
into an intensity and proportion score to compare to the S100A7 manual score. The area
scores for the percentage of area stained calculation are included in tables 4.13 - 4.15.
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The data provided in tables 4.13-4.15 is summarized in figures 4.11 and 4.12, with
average and median data provided. In these figures we can see that the average area
stained is greatest for the progressing group, as is the median percent area stained.
Table 4.13: Raw score for QuPath assessed epithelial area, S100A7 staining, and
percent of epithelium stained in a sub-population of Control tissue samples
Case
1
2
3
4
5
6
7
8
9
10

Control
Total
Stained
Area
Area
(µm2)
(µm2)
1632434 1021469
2937956 897673
2837717 747630
6697758 505108
8239414 8194281
1573195 962391
2336883 1246154
788825 119235
2623383 293613
3700602 1073271

Percent
stained
(%)
63
31
26
8
99
61
53
15
11
29

Table 4.14: Raw score for QuPath assessed epithelial area, S100A7 staining, and
percent of epithelium stained in a sub-population of the Non-progressing tissue
samples
Case
6
7
9
10
11
15
16
17
19
23

Non-progressing
Total
Stained
Area
Area
(µm2)
(µm2)
4142317 1031980
2022647 711778
2280948 971485
1269091 531520
3200509 1216982
7899666 6608
5117732 3947291
1857471 766041
2428462 978897
2634814 795521

Percent
stained
(%)
25
35
43
42
38
0.1
77
41
40
30
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Table 4.15: Raw score for QuPath assessed epithelial area, S100A7 staining, and
percent of epithelium stained in a sub-population of the Progressing tissue samples
Case
2
4
5
6
7
12
14
16
17
18

Progressing
Total
Stained
Area
Area
(µm2)
(µm2)
5587778 4520511
2444675 2444675
Tissue folds
11798099 8117504
1894655 1022796
1507748 1000659
549117
339161
11845915 7284297
4461147 1987904
5394605 2295742

Percent
stained
(%)
81
100
69
54
66
62
61
45
43

Figure 4.11: Average percent of epithelial area stained with S100A7 when assessed
with QuPath
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Figure 4.12: Median percent of epithelial area stained with S100A7 when assessed
with QuPath
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Figure 4.13 shows the scores for QuPath analysis for a subset of 10 cases from each of
the populations, when the data is converted to an intensity and proportion score. Figure
4.16 displays the S100A7 manual scores from the same subpopulation of tissue samples.
In general, the range of scores is reduced within the Progressing population when QuPath
was used for score. The average QuPath scores for the QuPath assessed populations is
4.2, 5.2, 6.6 (Figure 4.14), and the S100A7 manual score average is 4.3, 5.6, 4.9 (Figure
4.17).The median QuPath (Figure 4.15) score for the Control, Non-progressing and
Progressing groups were 3.5, 6, and 6.5, respectively, as compared to medians of 3.5, 5
and 5 respectively for the S100A7 manual score (Figure 4.18).
When QuPath was used to assess the tissue, the average and median intensity and
proportion scores are highest for the Progressing group (Figures 4.13 - 4.18). As the cases
selected were a small sub-sample of each of the populations, the average S100A7 manual
score was actually higher for the Non-progressing population compared to the
Progressing group (Figure 4.17)
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Figure 4.13: Dot Plot for the subpopulation QuPath S100A7 intensity and
proportion scores for each of the three populations
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Figure 4.14: Average intensity and proportion score for subpopulation of QuPath
assessed tissue samples when S100A7 area staining is assessed with QuPath
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Figure 4.15: Median intensity and proportion score for the subpopulation of
QuPath assessed tissue samples when S100A7 area staining is assessed with QuPath.
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Figure 4.16: Dot Plot for S100A7 manual scores for the subpopulation of the tissue
samples that underwent QuPath assessment
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Figure 4.17: Average S100A7 manual score for the subpopulation of QuPath
assessed tissue samples
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Figure 4.18: Median S100A7 manual score for the subpopulation of QuPath
assessed tissue samples
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4.4 MAPK Activated Phosphorylation Staining
Figures 4.19 - 4.27 demonstrates immunohistochemical staining of phosphorylated
MAPK pathway signaling proteins Erk1/2, p38, and JNK in the tissue samples. These
assays are interpreted to have failed, with diffuse, non-specific and extensive background
staining occurring in the tissue specimens. Staining for Erk1/2 shows cytoplasmic
staining with relative sparing of the nucleus and membrane (Figures 4.19 - 4.21). p38
staining also shows staining of the cytoplasm with nuclear sparing and sparing of the cell
membrane (Figures 4.22 - 4.24). Within the cytoplasm, the staining was uniform with
very little variation for both proteins. The JNK reagent was interpreted to have failed, as
no nuclear staining was apparent in known positive control tissue (Figures 4.25 - 4.27),
despite the use of several new antibody batches. As with the Erk1/2 and the p38, the
staining appears relatively even within the cytoplasm, sparing the nucleus and the cell
membrane.
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Figure 4.19: Erk1/2 Staining, Control group – Case 2 magnification (A) x100, (B)
x400

A
B
Figure 4.20: Erk1/2 Staining, Non-progressing group – Case 26 magnification (A)
x100, (B) x400

A
B
Figure 4.21: Erk1/2 Staining, Progressing group – Case 4 magnification (A) x100,
(B) x400

A

B
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Figure 4.22: p38 Staining, Control group – Case 2 magnification (A) x100, (B) x400

A
B
Figure 4.23: p38 Staining, Non-progressing group – Case 26 magnification (A) x100,
(B) x400

Figure 4.24: p38 Staining, Progressing group – Case 4 magnification (A) x100, (B)
x400
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Figure 4-25: JNK Staining, Control group – Case 2 magnification (A) x100, (B) x400

A
B
Figure 4.26: JNK Staining, Non-progressing group – Case 26 magnification (A)
x100, (B) x400

A
B
Figure 4.27: JNK Staining, Progressing group – Case 4 magnification (A) x100, (B)
x400
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4.5 Statistical analysis
4.5.1 Descriptive statistics
Table 4.16: Descriptive statistics for the 3-tier and 2-tier diagnoses, S100A7 manual
scoring, and Straticyte™ risk score
Descriptive
N

Mean

Std.
Std.
Deviation Error

95% Confidence
Interval for Mean

Lower
Upper
Bound
Bound
3-Tier 1
39
1.46
1.047
.168
1.12
1.80
2
35
1.09
.612
.103
.88
1.30
3
25
.00
.000
.000
.00
.00
Total 99
.96
.947
.095
.77
1.15
2-Tier 1
39
2.49
.885
.142
2.20
2.77
2
35
1.46
.852
.144
1.16
1.75
3
25
.00
.000
.000
.00
.00
Total 99
1.49
1.232
.124
1.25
1.74
Manual 1
39
5.74
1.888
.302
5.13
6.36
2
35
5.23
1.682
.284
4.65
5.81
3
25
4.00
1.708
.342
3.30
4.70
Total 99
5.12
1.886
.190
4.75
5.50
Straticyt 1
39
59.44 17.641
2.825 53.72
65.15
e
2
35
37.00 16.223
2.742 31.43
42.57
3
25
31.00 14.626
2.925 24.96
37.04
Total 99
44.32 20.486
2.059 40.24
48.41
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)

Minimu Maximu
m
m

0
0
0
0
1
1
0
0
2
2
2
2
21
12
3
3

3
2
0
3
3
3
0
3
8
8
8
8
85
71
63
85

The descriptive statistics for each of the predictive parameters for malignant
transformation are present in table 4.16. The sample populations were converted to
numerical titles for the purposes of statistical analysis. Population 1 is the Progressing
group, population 2 is the Non- progressing group and population 3 is the Control group.
For statistical analysis, the total number of samples included for the Progressing
population is 39, lower than the 48 total samples selected. This is due to the exclusion of
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five sets of data from the “Other” diagnoses for not being dysplasia, while an additional
four tissue samples due to tissue preparation issues such as tissue folds or poor
epithelium. In this case, Straticyte™ was not completed for any tissue sample which
contained any tissue folds. Therefore, a total of nine tissue samples was excluded (table
4.17). They remain in the raw data however, because they hold relevance for manual
scoring, 3-tier and 2-tier diagnoses
Table 4.17: Tissue samples excluded from statistical analysis and reason for
exclusion
Case number
5

Reason for exclusion
Tissue folds

16

TUGSE

24

Hyperplastic candidiasis

28

Lichenoid mucositis

40

Tissue lacking enough epithelium

43

Verrucous hyperplasia

50

Verrucous hyperplasia

61

Poor quality tissue section

63

Poor quality tissue section

Total

9
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Table 4.18: ANOVA output for 3 tier diagnosis, 2 tier diagnosis, manual S100A7
scores and Straticyte™ risk scores. The mean difference is significant at p<0.05
ANOVA
Sum of
df
Mean Square F
Squares
3-Tier
Between Groups 33.403
2
16.702
29.454
Within Groups 54.435
96
.567
Total
87.838
98
2-Tier
Between Groups 94.318
2
47.159
83.177
Within Groups 54.429
96
.567
Total
148.747
98
Manual Between Groups 46.938
2
23.469
7.470
Within Groups 301.607
96
3.142
Total
348.545
98
Straticyte Between Groups 15222.067
2
7611.033
28.203
Within Groups 25907.590
96
269.871
Total
41129.657
98
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)

Sig.
.000

.000

.001

.000

The ANOVA output is present in table 4.18. With this data analysis the goal is to
determine if there are statistically significant differences between the three populations,
Controls, Non-progressing, and Progressing for each of the predictive parameters. The
ANOVA indicates that within each of the study populations, there is a statistically
significant difference at p<0.05, that exists when each of the predictive parameters for
malignant transformation: 3-tier, 2-tier, S100A7 manual score, and Straticyte™ risk are
applied to the study populations. This means that the predictive parameters are able to
identify differences between the groups, however, ANOVA does not indicate between
which of the populations the difference exists.
4.5.2 Tukey multiple comparison 3-tier and 2-tier diagnoses
The 3-tier and 2-tier diagnoses were converted to numerical categories for the sake of
statistical analysis. The numerical conversion was as follows: hyperkeratosis/atypia 0,
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mild/low grade 1, moderate 2, and severe/high grade 3. While the ANOVA output (Table
4.19) indicates statistically significant differences for each of the two diagnostic
parameters, the differences are not clear as to between which populations the difference is
significant.
Table 4.19: Tukey multiple comparison between each of the populations (Control,
Non-progressing, Progressing) against one another with the 3-tier and 2-tier
diagnoses. Significance is achieved at p<0.05. Populations renamed for analysis (1:
Progressing, 2: Non-progressing, 3: Controls)
Multiple Comparisons
Dependent
(I)
(J)
Mean
Std.
Variable
Group Group Difference Error
(I- J)
1
Tukey
HSD
3-Tier

2
3
1

Bonferroni

2
3
1

Tukey
HSD
2-Tier

2
3
1

Bonferroni

2
3

2
3
1
3
1
2
2
3
1
3
1
2
2
3
1
3
1
2
2
3
1
3
1
2

.376
1.462*
-.376
1.086*
-1.462*
-1.086*
.376
1.462*
-.376
1.086*
-1.462*
-1.086*
1.030*
2.487*
-1.030*
1.457*
-2.487*
-1.457*
1.030*
2.487*
-1.030*
1.457*
-2.487*
-1.457*

.175
.193
.175
.197
.193
.197
.175
.193
.175
.197
.193
.197
.175
.193
.175
.197
.193
.197
.175
.193
.175
.197
.193
.197

Sig.

.087
.000
.087
.000
.000
.000
.104
.000
.104
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000
.000

95% Confidence Interval
Lower Bound Upper Bound
-.04
1.00
-.79
.62
-1.92
-1.56
-.05
.99
-.80
.61
-1.93
-1.57
.61
2.03
-1.45
.99
-2.95
-1.93
.60
2.02
-1.46
.98
-2.96
-1.94

.79
1.92
.04
1.56
-1.00
-.62
.80
1.93
.05
1.57
-.99
-.61
1.45
2.95
-.61
1.93
-2.03
-.99
1.46
2.96
-.60
1.94
-2.02
-.98
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*. The mean difference is significant at the 0.05 level.

Tukey multiple comparison for the 3-tier and 2-tier grading systems was performed. With
respect to the 3-tier diagnoses, the mean for the Progressing group was 1.46, the Nonprogressing group was 1.09, and the Control group was 0.0 (Table 4.16). According to
Tukey multiple comparison (Table 4.19), the difference between the Control group and
both dysplasia groups is statistically significant, however, the difference between the
Progressing and the Non-progressing group is not. The mean score for each of the
populations for the 2 tier diagnoses were 2.49, 1.46, and 0.0 for the Progressing, Nonprogressing and Control respectively (Table 4.16). The Tukey multiple comparison
(Table 4.19) indicates that the difference between each of the groups is statistically
significant at p<0.05.

100
4.5.3 Tukey multiple comparison S100A7 manual score
Table 4.20: Tukey multiple comparison between each of the populations (Control,
Non-progressing, Progressing) against one another with the manual S100A7 score.
Significance is achieved at p<0.05. Populations renamed for analysis (1: Progressing,
2: Non-progressing, 3: Controls)
Multiple Comparisons
Dependent
(I)
(J)
Mean
Std.
Variable
Group Group Difference Error
(I- J)
2
.515
.413
1
3
1.744*
.454
1
-.515
.413
2
3
1.229*
.464
Tukey
1
-1.744*
.454
HSD
3
2
-1.229*
.464
2
.515
.413
Manual
1
3
1.744*
.454
1
-.515
.413
2
3
1.229*
.464
Bonferroni
1
-1.744*
.454
3
2
-1.229*
.464
*. The mean difference is significant at the 0.05 level.
(Manual= S100A7 manual score)

Sig.

95% Confidence
Interval
Lower
Upper
Bound
Bound

.428
.001
.428
.025
.001
.025
.645
.001
.645
.028
.001
.028

-.47
.66
-1.50
.12
-2.82
-2.33
-.49
.64
-1.52
.10
-2.85
-2.36

1.50
2.82
.47
2.33
-.66
-.12
1.52
2.85
.49
2.36
-.64
-.10

The Tukey multiple comparison results from table 4.20 allow us to see if there are
significant differences between each of the populations with respect to S100A7 manual
scoring. From table 4.16, the mean S100A7 manual score for each of the populations was
5.74, 5.23, and 4.0 for the Progressing, Non-progressing, and Control groups
respectively. From the Tukey multiple comparison table, these differences are statistically
significant between the Control population and the two dysplastic populations, however,
there is no statistical difference between the Non-progressing and Progressing groups.
The difference is significant at p<0.05.
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4.5.4 Tukey multiple comparison, Straticyte™ risk score
Table 4.21: Tukey multiple comparison between each of the populations (Controls,
Non-progressing, Progressing) against one another with the Straticyte™ Risk Score.
Significance is achieved at p<0.05. Populations renamed for analysis (1: Progressing,
2: Non-progressing, 3: Controls)
Multiple Comparisons
Dependent Variable (I)
(J)
Mean
Std.
Group Group Difference Error
(I- J)
2
22.436*
3.825
1
3
28.436*
4.209
1
-22.436* 3.825
2
3
6.000
4.302
Tukey
1
-28.436* 4.209
HSD
3
2
-6.000
4.302
2
22.436*
3.825
Straticyte
1
3
28.436*
4.209
1
-22.436* 3.825
2
3
6.000
4.302
Bonferroni
1
-28.436* 4.209
3
2
-6.000
4.302
*. The mean difference is significant at the 0.05 level.
(Straticyte= Straticyte risk score)

Sig.

95% Confidence
Interval
Lower
Upper
Bound
Bound

.000
.000
.000
.348
.000
.348
.000
.000
.000
.499
.000
.499

13.33
18.42
-31.54
-4.24
-38.46
-16.24
13.12
18.18
-31.76
-4.48
-38.69
-16.48

31.54
38.46
-13.33
16.24
-18.42
4.24
31.76
38.69
-13.12
16.48
-18.18
4.48

The statistical data for the Straticyte™ risk score is also included in table 4.16. The
average percent risk for the three populations are 59.44, 37.00 and 31.00, for the
Progressing to OSCC, Non-progressing, and Hyperkeratosis/Control groups respectively.
When Tukey multiple comparison is applied (Table 4.21), the difference between the
Progressing to OSCC group and both the Non-progressing dysplasia and
Hyperkeratosis/Control groups is statistically significant at p<0.05. The difference
between the Non-progressing dysplasia group and the Hyperkeratosis/Control groups is
non-significant.
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4.5.5 Tukey multiple comparison, QuPath score
A total of 29 tissue samples were assessed with QuPath. Ten tissue samples from each of
the populations was originally selected, however case 5 in the Progressing group was not
scored by Straticyte because of tissue folds, therefore this group only had 9 cases.
Table 4.22: Descriptive statistics for the 3-tier and 2-tier diagnoses, S100A7 manual
score, Straticyte™ risk score and QuPath score for the subpopulation of QuPath
tested tissue samples
Descriptives
N

Mean Std.
Std. 95% Confidence
Deviation Error Interval for Mean

Lower
Upper
Bound
Bound
3-Tier 1
9
1.11 1.054
.351 .30
1.92
2
10
1.50 .707
.224 .99
2.01
3
10
.00
.000
.000 .00
.00
Total29
.86
.953
.177 .50
1.22
2-Tier 1
9
1.78 .972
.324 1.03
2.52
2
10
2.20 1.033
.327 1.46
2.94
3
10
.00
.000
.000 .00
.00
Total29
1.31 1.257
.233 .83
1.79
Manual 1
9
4.78 1.986
.662 3.25
6.30
2
10
5.60 1.578
.499 4.47
6.73
3
10
4.30 2.003
.633 2.87
5.73
Total29
4.90 1.877
.349 4.18
5.61
Straticyte 1
9
52.11 22.048 7.349 35.16
69.06
2
10
38.80 15.591 4.930 27.65
49.95
3
10
31.20 12.109 3.829 22.54
39.86
Total29
40.31 18.422 3.421 33.30
47.32
Qupath 1
9
6.67 1.000
.333 5.90
7.44
2
10
5.20 1.619
.512 4.04
6.36
3
10
4.20 1.932
.611 2.82
5.58
Total29
5.31 1.834
.341 4.61
6.01
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)

Minimum Maximum

0
0
0
0
1
1
0
0
2
4
2
2
22
15
15
15
5
2
2
2

3
2
0
3
3
3
0
3
8
8
8
8
75
59
55
75
8
7
8
8
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Table 4.23: Tukey multiple comparison between each of the populations (Control,
Non-progressing, Progressing) against one another with the 3-tier, 2-tier, S100A7
manual score, Straticyte™ risk score and QuPath score. Significance is achieved at
p<0.05. Populations renamed for analysis (1: Progressing, 2: Non-progressing, 3:
Control)
Multiple Comparisons
Dependent
(I)
(J)
Mean
Std.
Variable
Group Group Difference Error
(I- J)
3-Tier Tukey
HSD

1
2
3

Bonferroni 1
2
3
2-Tier Tukey
HSD

1
2
3

Bonferroni 1
2
3

2
3
1
3
1
2
2
3
1
3
1
2
2
3
1
3
1
2
2
3
1
3
1
2

-.389
1.111*
.389
1.500*
-1.111*
-1.500*
-.389
1.111*
.389
1.500*
-1.111*
-1.500*
-.422
1.778*
.422
2.200*
-1.778*
-2.200*
-.422
1.778*
.422
2.200*
-1.778*
-2.200*

.330
.330
.330
.321
.330
.321
.330
.330
.330
.321
.330
.321
.373
.373
.373
.363
.373
.363
.373
.373
.373
.363
.373
.363

Sig.

95% Confidence
Interval
Lower
Upper
Bound
Bound

.476
.006
.476
.000
.006
.000
.747
.007
.747
.000
.007
.000
.504
.000
.504
.000
.000
.000
.805
.000
.805
.000
.000
.000

-1.21
.29
-.43
.70
-1.93
-2.30
-1.23
.27
-.45
.68
-1.95
-2.32
-1.35
.85
-.51
1.30
-2.71
-3.10
-1.38
.82
-.53
1.27
-2.73
-3.13

.43
1.93
1.21
2.30
-.29
-.70
.45
1.95
1.23
2.32
-.27
-.68
.51
2.71
1.35
3.10
-.85
-1.30
.53
2.73
1.38
3.13
-.82
-1.27
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Manual Tukey
HSD

1

2
-.822
.855
.607
-2.95
3
.478
.855
.843
-1.65
2
1
.822
.855
.607
-1.30
3
1.300
.832
.280
-.77
3
1
-.478
.855
.843
-2.60
2
-1.300
.832
.280
-3.37
Bonferroni 1
2
-.822
.855
1.000 -3.01
3
.478
.855
1.000 -1.71
2
1
.822
.855
1.000 -1.37
3
1.300
.832
.391
-.83
3
1
-.478
.855
1.000 -2.67
2
-1.300
.832
.391
-3.43
Straticyte Tukey
1
2
13.311
7.749 .218
-5.95
HSD
3
20.911*
7.749 .031
1.65
2
1
-13.311
7.749 .218
-32.57
3
7.600
7.543 .579
-11.14
3
1
-20.911* 7.749 .031
-40.17
2
-7.600
7.543 .579
-26.34
Bonferroni 1
2
13.311
7.749 .293
-6.52
3
20.911*
7.749 .036
1.08
2
1
-13.311
7.749 .293
-33.14
3
7.600
7.543 .969
-11.70
3
1
-20.911* 7.749 .036
-40.74
2
-7.600
7.543 .969
-26.90
Qupath Tukey
1
2
1.467
.728
.128
-.34
HSD
3
2.467*
.728
.006
.66
2
1
-1.467
.728
.128
-3.27
3
1.000
.708
.350
-.76
3
1
-2.467*
.728
.006
-4.27
2
-1.000
.708
.350
-2.76
Bonferroni 1
2
1.467
.728
.163
-.40
3
2.467*
.728
.007
.60
2
1
-1.467
.728
.163
-3.33
3
1.000
.708
.509
-.81
3
1
-2.467*
.728
.007
-4.33
2
-1.000
.708
.509
-2.81
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
*. The mean difference is significant at the 0.05 level.

1.30
2.60
2.95
3.37
1.65
.77
1.37
2.67
3.01
3.43
1.71
.83
32.57
40.17
5.95
26.34
-1.65
11.14
33.14
40.74
6.52
26.90
-1.08
11.70
3.27
4.27
.34
2.76
-.66
.76
3.33
4.33
.40
2.81
-.60
.81
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Table 4.22 contains the descriptive statistics for the tissue samples that were assessed
with QuPath. For these samples, table 4.23 contains the Tukey analysis to determine if
differences found between the populations is significant. The Tukey analysis for the
smaller sample size for the Manual S100A7 scores demonstrates that there is a
statistically significant difference in the scores for the Progressing and Control group, but
not the Non-progressing group. There was no statistically significant difference between
the Non-progressing and Control groups either. The same can be said for the Straticyte™
assessment, in which the difference between the Progressing and Control groups was
statistically significant, yet it was not significant in distinguishing the Progressing from
the Non-progressing. The Non-progressing and Controls are also not statistically
different.
With the QuPath assessment the same statistical methods were used. The mean score for
each of the populations for QuPath was 6.67, 5.20 and 4.20 for the Progressing, Nonprogressing and the Control groups respectively (table 4.22). With the Tukey multiple
comparison (table 4.23), only the difference between the Progressing and Control was
statistically significant. For the Non-Progressing group, just as it was for the Manual
S100A7 score and Straticyte scores, there was no statistically significant difference with
either of the other two groups.
4.5.6 Pearson correlation coefficients
Correlational statistics for 3-tier, 2-tier, S100A7 manual score and Straticyte™ risk score
The Pearson Correlation Coefficient allows for comparison of the different predictive
parameters of malignant transformation with one another to determine if there is a
correlational relationship between them. When analyzed, relationships deemed very
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strong have correlational coefficient closer to one (156). The significance of these
relationships is indicated by the asterisk with p- values less than 0.01 or 0.05 in the tables
below.
Table 4.24: All populations. Pearson correlation coefficient table for the 3-tier, 2tier, S100A7 manual score, and Straticyte™ risk score.
Correlations
3-Tier
2-Tier
Manual
3-Tier
Pearson Correlation 1
.673**
.329**
Sig. (2-tailed)
.000
.001
N
99
99
99
2-Tier
Pearson Correlation .673**
1
.321**
Sig. (2-tailed)
.000
.001
N
99
99
99
Manual
Pearson Correlation .329**
.321**
1
Sig. (2-tailed)
.001
.001
N
99
99
99
Straticyte Pearson Correlation .422**
.520**
.669**
Sig. (2-tailed)
.000
.000
.000
N
99
99
99
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).

Straticyte
.422**
.000
99
.520**
.000
99
.669**
.000
99
1
99

The 3-tier diagnosis has weak correlation with the S100A7 manual score, at 0.329, and
moderate correlation with the Straticyte™ risk score with a correlational coefficient of
0.422. Both of these correlations are statistically significant at p<0.01.
The 2-tier system had similar correlation with the S100A7 manual score, with a
coefficient of 0.321, however had a slightly improved correlation with the Straticyte™
risk score at 0.520, indicating moderate correlation as well. Again, these relationships are
statistically significant at p<0.01.
The correlational coefficient between The S100A7 manual score and the Straticyte™ risk
score was 0.669, which also indicates a moderate correlation between the two diagnostic
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approaches, and assessment of S100A7. The correlational relationship is statistically
significant at p<0.01.
Further Pearson Correlation was completed for each of the three sample populations to
determine if the relationships between any of the diagnostic tests and specific populations
were different from the overall population.
Table 4.25: Progressing population. Pearson correlation coefficient table for the 3tier, 2-tier, S100A7 manual score, and Straticyte™ risk score
Correlations
3-Tier
2-Tier
Manual
3-Tier
Pearson Correlation 1
.376*
.234
Sig. (2-tailed)
.018
.151
N
39
39
39
2-Tier
Pearson Correlation .376*
1
.014
Sig. (2-tailed)
.018
.934
N
39
39
39
Manual
Pearson Correlation .234
.014
1
Sig. (2-tailed)
.151
.934
N
39
39
39
Straticyte Pearson Correlation .241
.082
.595**
Sig. (2-tailed)
.140
.619
.000
N
39
39
39
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).

Straticyte
.241
.140
39
.082
.619
39
.595**
.000
39
1
39

For the Progressing population alone, the strongest correlational relationship is between
the S100A7 manual score, and the Straticyte™ risk score. The correlation coefficient is
0.595, a moderate strength relationship, with statistical significance at p<0.01 (Table
4.25).
The correlational relationships for both the 3-tier and 2-tier with the S100A7 manual
score and the Straticyte™ risk score both worsened. Negligible correlation existed
between the 2-tier and the S100A7 manual score, (correlation coefficient 0.014), and the
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2-tier and the Straticyte™ risk score, (correlation coefficient 0.082). Neither of these
relationships, however, are statistically significant (Table 4.25). The 3-tier system faired
only slightly better with correlation coefficients of 0.234 and 0.241 with the S100A7
manual score and the Straticyte™ risk score respectively. Again, neither of these were
considered statistically significant.
Table 4.26: Non-progressing population. Pearson correlation coefficient table for
the 3-tier, 2-tier, S100A7 manual score, and Straticyte™ risk score
Correlations
3-Tier
2-Tier
Manual
3-Tier
Pearson Correlation 1
.486**
.009
Sig. (2-tailed)
.003
.959
N
35
35
35
2-Tier
Pearson Correlation .486**
1
.130
Sig. (2-tailed)
.003
.456
N
35
35
35
Manual
Pearson Correlation .009
.130
1
Sig. (2-tailed)
.959
.456
N
35
35
35
Straticyte Pearson Correlation .145
.311
.691**
Sig. (2-tailed)
.406
.069
.000
N
35
35
35
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
** Correlation is significant at the 0.01 level (2-tailed).
Correlation is significant at the 0.05 level (2-tailed).

Straticyte
.145
.406
35
.311
.069
35
.691**
.000
35
1
35

The correlation coefficients for the Non-progressing population are presented in table
4.26. The correlation between the 3-tier and 2-tier is moderate at 0.486 and is statistically
significant at p<0.01. However, the relationship between the 2-tier with the S100A7
manual score and the Straticyte™ risk score, are weak with coefficients of 0.130 and
0.311 respectively, both of which are not statistically significant. The 3-tier had
negligible correlation with the S100A7 manual score, (correlation coefficient 0.009), and
weak correlation, (correlation coefficient 0.130), with the Straticyte™ risk score. Neither

109
are statistically significant. The correlation for the S100A7 manual score with the
Straticyte™ risk score was (correlation coefficient 0.691), moderately strong, and
statistically significant at p<0.01.
Table 4.27: Control population. Pearson correlation coefficient table for the 3-tier,
2-tier, S100A7 manual score, and Straticyte™ risk score.
Correlations
3-Tier
2-Tier
Manual
3-Tier
Pearson Correlation .a
.a
.a
Sig. (2-tailed)
.
.
N
25
25
25
2-Tier
Pearson Correlation .a
.a
.a
Sig. (2-tailed)
.
.
N
25
25
25
Manual
Pearson Correlation .a
.a
1
Sig. (2-tailed)
.
.
N
25
25
25
Straticyte Pearson Correlation .a
.a
.712**
Sig. (2-tailed)
.
.
.000
N
25
25
25
(Manual= Manual S100A7 score; Straticyte= Straticyte™ risk score)
a. Cannot be computed because at least one of the variables is constant.
** Correlation is significant at the 0.01 level (2-tailed).
Correlation is significant at the 0.05 level (2-tailed).

Straticyte
.a
.
25
.a
.
25
.712**
.000
25
1
25

The correlation coefficients for the Control population is present in Table 4.27. Due to
the lack of variance in the 3-tier and 2-tier diagnoses, they are interpreted as constants,
therefore they cannot be used in correlational coefficient calculations. The correlation
coefficient for the S100A7 manual score with the Straticyte™ risk score was 0.692,
which is moderately strong, and statistically significant at p<0.01.
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4.5.7 QuPath correlation
Table 4.28: All Populations. Pearson correlation coefficient table for the 3-tier, 2tier,
S100A7 manual score, and Straticyte™ risk score and QuPath
Correlations
3-Tier
2-Tier
Manual Straticyte
3-Tier
Pearson Correlation 1
.663**
.391*
.438*
Sig. (2-tailed)
.000
.036
.018
N
29
29
29
29
2-Tier
Pearson Correlation .663**
1
.105
.381*
Sig. (2-tailed)
.000
.588
.041
N
29
29
29
29
Manual
Pearson Correlation .391*
.105
1
.538**
Sig. (2-tailed)
.036
.588
.003
N
29
29
29
29
Straticyte Pearson Correlation .438*
.381*
.538**
1
Sig. (2-tailed)
.018
.041
.003
N
29
29
29
29
Qupath
Pearson Correlation .311
.298
.632**
.533**
Sig. (2-tailed)
.100
.117
.000
.003
N
29
29
29
29
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
** Correlation is significant at the 0.01 level (2-tailed).
Correlation is significant at the 0.05 level (2-tailed).

Qupath
.311
.100
29
.298
.117
29
.632**
.000
29
.533**
.003
29
1
29

The All population Pearson correlation for the 29 QuPath tissue samples is present in
table 4.28. The primary focus is the QuPath result and whether or not correlational
relationships exist for the sample populations with the other predictive parameters.
QuPath correlates weakly with both the 3-tier and 2-tier diagnoses with no statistical
significance. It correlates moderately with both the S100A7 manual score, and the
Straticyte™ risk score with correlational coefficients of 0.632, and 0.533 respectively.
Both relationships are statistically significant at p<0.01
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Table 4.29: Progressing population. Pearson correlation coefficient table for the 3tier, 2-tier, S100A7 manual score, and Straticyte™ risk score and QuPath
Correlations
3-Tier
2-Tier
Manual Straticyte
3-Tier
Pearson Correlation 1
.027
.610
.371
Sig. (2-tailed)
.945
.081
.326
N
9
9
9
9
2-Tier
Pearson Correlation .027
1
-.353
.042
Sig. (2-tailed)
.945
.352
.914
N
9
9
9
9
Manual
Pearson Correlation .610
-.353
1
.514
Sig. (2-tailed)
.081
.352
.156
N
9
9
9
9
Straticyte Pearson Correlation .371
.042
.514
1
Sig. (2-tailed)
.326
.914
.156
N
9
9
9
9
Qupath
Pearson Correlation .158
-.214
.713*
.291
Sig. (2-tailed)
.685
.580
.031
.447
N
9
9
9
9
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
Correlation is significant at the 0.05 level (2-tailed)

Qupath
.158
.685
9
-.214
.580
9
.713*
.031
9
.291
.447
9
1
9

The Progressing population of QuPath assessed tissue samples underwent Pearson
correlation, presented in table 4.29. The correlation coefficient for the QuPath score and
the S100A7 manual score is 0.713, which is considered a strong correlation relationship.
The relationship is significant to p<0.01. For the Non-progressing population, the
correlation coefficients between QuPath and the S100A7 manual score as well as the
Starticyte™ were 0.513 and 0.195 respectively, which are considered moderate and weak
correlational relationships. Neither of these relationships are statistically significant (table
4.30). For the Control group, the lack of variance in the 3-tier and 2-tier diagnoses creates
constants for each and therefore these cannot be used for correlational assessment. The
correlational relationship for QuPath with the S100A7 manual score and Straticyte™ risk
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for the Control group are (correlation coefficients 0.959 and 0.767). These are also both
significant at p<0.01 (table 4.31). These relationships are considered very strong and
strong respectively.
Table 4.30: Non-progressing. Pearson correlation coefficient table for the 3-tier, 2tier, S100A7 manual score, and Straticyte™ risk score and QuPath
Correlations
3-Tier
2-Tier
Manual Straticyte
3-Tier
Pearson Correlation 1
.609
.000
.514
Sig. (2-tailed)
.062
1.000
.129
N
10
10
10
10
2-Tier
Pearson Correlation .609
1
-.082
.582
Sig. (2-tailed)
.062
.822
.077
N
10
10
10
10
Manual
Pearson Correlation .000
-.082
1
.593
Sig. (2-tailed)
1.000
.822
.071
N
10
10
10
10
Straticyte Pearson Correlation .514
.582
.593
1
Sig. (2-tailed)
.129
.077
.071
N
10
10
10
10
Qupath
Pearson Correlation .194
.106
.513
.195
Sig. (2-tailed)
.591
.770
.129
.588
N
10
10
10
10
(Manual= S100A7manual score; Straticyte= Straticyte™ risk score)
Correlation is significant at the 0.05 level (2-tailed).

Qupath
.194
.591
10
.106
.770
10
.513
.129
10
.195
.588
10
1
10
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Table 4.31: Control population. Pearson correlation coefficient table for the 3-tier,
2-tier, S100A7 manual score, and Straticyte™ risk score and QuPath
Correlations
3-Tier
2-Tier
Manual Straticyte
3-Tier
Pearson Correlation .a
.a
.a
.a
Sig. (2-tailed)
.
.
.
N
10
10
10
10
2-Tier
Pearson Correlation .a
.a
.a
.a
Sig. (2-tailed)
.
.
.
N
10
10
10
10
Manual
Pearson Correlation .a
.a
1
.817**
Sig. (2-tailed)
.
.
.004
N
10
10
10
10
Straticyte Pearson Correlation .a
.a
.817**
1
Sig. (2-tailed)
.
.
.004
N
10
10
10
10
Qupath
Pearson Correlation .a
.a
.959**
.767**
Sig. (2-tailed)
.
.
.000
.010
N
10
10
10
10
(Manual= S100A7 manual score; Straticyte= Straticyte™ risk score)
a. Cannot be computed because at least one of the variables is constant.
** Correlation is significant at the 0.01 level (2-tailed).
Correlation is significant at the 0.05 level (2-tailed).

Qupath
.a
.
10
.a
.
10
.959**
.000
10
.767**
.010
10
1
10
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CHAPTER 5: DISCUSSION
5.1 Demographics
5.1.1 Gender
In general, there was relative gender equality between the Hyperkeratosis/Control
(Control), Non-progressing dysplasia (Non-progressing) and Progressing to OSCC
(Progressing) populations in this study. The current literature is often mixed with respect
to gender differences and OPMLs, and any gender predilection may be linked to habits
(59) (156). Interestingly, while lesions maybe reported to occur in males more frequently
than in females, malignant transformation has been shown to occur more frequently in the
latter (69). It has been shown that women without oral habits such as tobacco use or
alcohol consumption are at greater risk of malignant transformation than those that use
tobacco and alcohol (84). In this current study, 2 of the 13 cases that had known tobacco
consumption were women, though we were unable to draw any strong conclusions
regarding malignant transformation and oral habits given the lack of information
regarding tobacco and alcohol use.
5.1.2 Age
The average age at initial biopsy for each of the populations was also noted. The average
age and age range of the Control group was 50.4 years with a range of 15-72 years, while
the Non-progressing group was 55.4 years, with a range of 31-74 years and the
Progressing group was 62.2 years with a range of 40-86 years. The younger age at initial
biopsy for the Control group may reflect a significant outlier within the group, as there
was a patient whose initial biopsy was at 15 years old which is 16 years younger than the
youngest patient in the Non-progressing group. With this outlier removed, the average
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age for the Control group was 52 years old, an increase of only 2 years, which is still
younger than the other two groups. Median age of the Progressing group was 62, the
Non-progressing was 59, and the Control group was 51 years. This is similar to the
difference in average age. While Leukoplakia can occur within a large age range, it is
most commonly detected in the forth to seventh decades of life in North America,
therefore our findings are in keeping with expectation with published literature (59).
5.1.3 Lesion Location
In this study, the most common lesion sites were the lateral tongue, ventral tongue and
floor of mouth (table 4.4). These are all contiguous anatomic sites and are often cited as
the most common site for oral dysplastic lesions (69)(3)(66). In all three populations,
these were the most common sites to be biopsied with a total of 38 lesions from the
lateral tongue and 34 lesions from the ventral tongue and floor of mouth out of a total of
108 lesions. Of the 72 lesions from these sites, 28 (39%) underwent malignant
transformation. This transformation rate is higher than other studies which site
transformation rates for the tongue with or without floor of mouth as 27%, 14.9%, and
11.8% (82)(84)(66).
Interestingly, amongst the three populations, buccal mucosa lesions were only seen
within the Progressing group. A total of six biopsies were obtained from this site.
Evidence regarding the frequency of buccal mucosal lesions is mixed. Buccal mucosal
leukoplakia has been found to occur commonly in some studies, with leukoplakia at this
site occurring nearly as frequently as the lateroventral tongue and floor of mouth
(157)(79) (66)(158). In one particular study, the buccal mucosa was the most common
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site for lesions, however these were reported as oral leukoplakia and strongly effected by
oral habits such as tobacco and betel quid chewing. With cessation of these habits, many
of the lesions resolved. Dysplasia within the buccal mucosa was not common in this
study (159). Other studies indicate that the occurrence of buccal mucosal dysplasia and
OSCC are not common. A study from Spain found only 7.7% of the major head and neck
cancer cases they managed had OSCC of the buccal mucosa (11). In another study by
Dost, 260 lesions were compared for site, and histological diagnoses. 79 lesions were
found on the buccal mucosa, 41 (52%) were mild dysplasia, and none were OSCC (66).
These results are corroborated by a Hungarian study where 170/670 lesions occurred on
the buccal mucosa, however, only 5 transformed into OSCC (82). In our current study,
the patients with buccal lesions were 77, 71, 48, 81, 82, 43 years of age (average: 67). In
a study by Silverman et al, age was evaluated for each of the lesion locations, and they
found the average age for patients with buccal leukoplakia which converted to OSCC was
60 years old. This was slightly older than the average age for all patients with lesions
which was 57 years. This difference in age was not found to be significant in this study,
and the age for each of the lesion locations was roughly the same whether they
transformed or not (3). A Brazilian study from 2020, found no significant difference in
lesion location and age (61).
Actinic cheilitis of the lower lip was only seen in the group that progressed to OSCC as
well. In a 2018 systematic review, the malignant transformation rate was found to be
3.07% for actinic cheilitis (160).
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These results may reflect a selection or sample bias based on our initial search criteria.
Each of the tissue samples are provided a numerical code based on diagnoses and are
logged within a database for the division of Oral Pathology at Western University and
London Health Sciences Centre. As part of the search criteria, this numerical code was
used to identify tissue samples of a given diagnosis. The lesions that progressed to OSCC
from a previous lesion would have been found based on the OSCC code, not that of the
original diagnosis. The dysplastic lesions that did not progress to OSCC would have been
identified based on a dysplasia code. Actinic cheilitis was coded separately from
dysplasia, and would not have been included in the search for hyperkeratosis or
dysplastic lesions that do not progress, which would contribute to the discrepancy seen.
The same could be said for non-progressing buccal lesions, if they were characterized as
a different diagnosis on initial biopsy. This could occur due to the high rate of other
types of lesions occurring within the buccal mucosa as previously noted, and potential
difficulty differentiating between mild dysplastic and non-dysplastic changes.
5.1.4 Malignant Transformation
In the current study, 48 tissue samples were selected that eventually progressed to OSCC.
Of these tissue samples, the average time to malignant transformation was 4.36 years
(range <1-13 years). This is in keeping with a recent systematic review and metaanalysis, in which four studies assessed time to malignant transformation within oral
dysplastic tissue samples. In that study, the average time to malignant transformation
based on these four studies was 4.3 years (range 0.5-16 years) (161). A more recent study
reports a mean transformation rate of 33.56 months (2.8 years) with a range of 6-67
months (0.5-5.58 years) (162).
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5.2 Utility of predictive parameters of dysplasia
5.2.1 3-Tier and 2-Tier dysplasia grading systems
Three-tier and 2-tier dysplasia grading systems were evaluated both individually and also
compared to one another to determine their utility in predicting malignant transformation.
Historically, the 3-tier diagnosis is known to be problematic given the issues regarding
inter-observer and intra-observer variability (98)(99)(100). In addition, difficulty arises
in differentiating neoplastic mild and moderate dysplasia from non-neoplastic mild
dysplastic changes based on histomorphology alone, particularly in inflamed tissue (163).
With respect to the Non-progressing dysplasia population, mild dysplasia was the most
frequent 3-tier diagnosis and low-grade dysplasia was the most frequent 2-tier diagnosis.
None of the tissue samples contained severe dysplasia, though 8 of the tissue samples
were interpreted as high grade according to the 2-tier system. Interestingly these do not
all coincide with the 8 cases of moderate dysplasia and demonstrates the variability of
histopathological interpretation.
The group that progressed to OSCC contained 11 tissue samples with mild dysplasia, 13
tissue samples with moderate dysplasia, and 5 tissue samples with severe dysplasia. In
addition, diagnoses also included TUGSE, hyperkeratosis, lichenoid mucositis, and
verrucous hyperplasia. While TUGSE and hyperkeratosis are not included in the list of
OPMLs, lichenoid mucositis and verrucous hyperplasia are (56). When the lesions were
re-evaluated with the 2-tier system, 10 lesions contained low grade dysplasia, while 33
contained high grade dysplasia.
The two dysplastic populations, Non-progressing and Progressing, both contain mild,
moderate and severe dysplastic tissue when evaluated with the 3-tier system. When
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evaluated with the 2- tier system a combination of low grade and high grade was present
in both. While high or severe grade dysplastic lesions carry greater risk of malignant
transformation, and the low grade or mild dysplasia caries a lower risk, we found
inconsistency in the grading scales ability to truly identify lesions that will progress to
OSCC as compared to those that do not, which has often been reported (64)(94). In
addition, some lesions without signs of dysplasia or leukoplakia can progress (3). In the
current study, 32% of total mild dysplasia progressed to OSCC, and 100% of severe
lesions progressed. When utilizing the 2-tier grading system, 80% of the high grade
lesions progressed, and 27% of the low grade progressed. In addition, nine lesions with
squamous or architectural atypia progressed to OSCC, highlighting the difficulty with the
grading systems (164). The progression of the severe dysplasia within our study may also
be a result of selection bias as it was discussed earlier that the greatest difficulty lies in
identifying mild dysplasias, therefore more emphasis was placed on finding lesions with
mild or moderate grade dysplasia as an attempt to underscore potential differences in
S100A7 staining.
In this study, a moderate correlation was found between the 3-tier and 2-tier grading
systems when all populations were considered together (table 4.21). When correlating
grading systems with each population individually, the relationship was moderate for the
Non-progressing group, which was stronger than for the Progressing group (tables 4.22,
4.23). The stronger correlation found between the two grading systems in the Nonprogressing group may be explained by the number of moderate cases in each of the
populations. There were 13 moderate dysplasia cases in the Progressing group, and only
8 in the Non-progressing group. Given the difficulty with distinguishing moderate
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dysplasia in the 3-tier system, the greater number of moderate dysplasia cases could be a
contributing factor to greater variability in the Progressing 3-tier diagnoses, which would
effect the correlation of the two populations. (163).
The use of the 3-tier grading system enabled the pathologist to differentiate the dysplastic
populations from the Control population but not the Progressing and the Non-progressing
populations, when Tukey analysis was applied (table 4.16). This is consistent with what
would be expected in the literature, as lesions with more significant changes are more
readily agreed upon and distinguishable from non-dysplastic lesions. As such the
hyperkeratosis of the Control group should be readily identifiable as compared to most
dysplastic tissue. Distinguishing between the Non-progressing and Progressing groups is
difficult as the visual assessment of the tissue samples and identification of dysplasia is
the same, therefore the expectation would be that the tissue samples with minimal or no
changes would be identifiable when compared to those with significant change (165)
(166).
The 2-tier grading system improved upon the 3-tier system. When comparing the three
study populations, the 2-tier allowed the examiner to differentiate between not only the
dysplastic and non-dysplastic lesions, but between the Progressing and Non-progressing
as well (table 4.16). This ability to characterize the tissue samples in our study is in
keeping with previous studies regarding the binary grading system (95). This may be due
to the removal of moderate dysplastic lesions as seen in the 3-tier system, which has been
problematic for pathologist in determining risk of malignant transformation (163).
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5.2.2 S100A7 manual score
In this study, the potential utility of S100A7 expression as a biomarker for predicting
malignant transformation of dysplastic lesions was assessed. Our expectation was that
high expression of S100A7 within the epithelium of an oral mucosal dysplastic lesion
was indicative of increased risk of malignant transformation.
S100A7 expression was found in all three of the populations evaluated. Staining tended
to spare the basal layer, and was most prevalent in the stratum spinosum and the stratum
granulosum when present. In tissue sections with very heavy staining, faint staining
within the basal layer was appreciated. This is consistent with other studies assessing
S100A7 manual scoring of epithelial dysplasia (121).
There was a general trend toward higher total manual score within both the Nonprogressing and Progressing groups as compared to the Control group. This finding is in
keeping with literature that noted increased expression of S100A7 in tissue with dysplasia
relative to histologically normal tissue (129). The Progressing group demonstrated
greater expression of S100A7 than the Non-progressing group. When ANOVA was
applied to the population data for S100A7, it was noted that there was a statistically
significant difference between these populations, and on further statistical analysis,
utilizing Tukey multiple comparisons, the S100A7 manual score provided the examiner
information to allow them to differentiate the two dysplastic populations from the Control
population, however, the S100A7 manual score did not provide utility in allowing the
examiner to differentiate the Non-progressing from the Progressing populations. This is
clinically important as differentiating dysplastic from non-dysplastic tissue is currently
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the basis of the 3-tier and 2-tier systems, and the additional information gained from
S100A7 manual scoring may effect the clinical follow up of a patient. Dysplastic tissues
are considered to be at increased risk of malignant transformation; yet a significant
number of lesions deemed non-OPMLs also progress to OSCC (167). The S100A7
manual score can be applied with little additional effort to tissue samples from the oral
cavity, and may contribute to an increased index of suspicion regarding malignant
potential of a lesion. The diagnosis of dysplasia increases the frequency with which
patients are followed clinically, therefore an assumption can be made that if a lesion is
not identified as an OPML, the frequency in which they are followed will remain low.
While there is no evidence based clinical follow up regimen, those diagnosed with
OPMLs are seen at greater frequency, usually every 3-12 months (105)(87). A set of
patients may be identified with the S100A7 manual score that are mild dysplasia or nonOPMLs but carry an increased risk of malignant transformation.
In order to determine a malignant transformation risk based on S100A7
immunohistochemical staining, further work is required to determine a cut off-score that
would be specific enough to limit the number of cases deemed high risk, but also
sensitive enough to include patients that are truly at risk. A validation study will be
required to determine a threshold for risk. This could be completed by the same
pathologist, or group of pathologists in order to establish a threshold for which amount of
staining is significant. Based on this study, the average score for the Progressing group
was 5.74, with a 95% confidence interval of 5.13 to 6.36, therefore any lesion with a
manual score over five should be carefully followed. The S100A7 manual score in this
study was unable to provide information that allowed the examiner to differentiate the
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Non-progressing from the progressing group, and so it could be speculated that there
would be a number of patients with dysplasia and a manual score below five that would
likely have a lower risk of progression.
5.2.3 Straticyte™ assay for S100A7 staining
Straticyte™ is used to assess S100A7 staining according to a proprietary algorithm, to
formulate a five year risk score for malignant transformation (132). Our study
demonstrated through Tukey analysis that Straticyte™ has the ability to differentiate a
Progressing group from a Non-progressing group of dysplastic tissue (table 4.18). This
holds diagnostic importance, as differentiating lesions that progress from those that do
not is an area of weakness for the commonly used 3-tier grading system (57)(101)(164).
This result supports the work by Hwang et al, in that the quantitative assessment of
S100A7 staining of dysplastic oral epithelium utilizing Straticyte™ demonstrates an
ability to differentiate lesions that do transform to OSCC from those that do not (132).
This allows for closer follow up of oral epithelial lesions with increased risk of malignant
transformation, as opposed to all patients with apparent dysplasia, which could
potentially be inflammatory and likely to not progress. As such, there is utility in
Straticyte™ based on our study, as it will increase efficiency for clinicians by identifying
those at greater risk of malignant transformation. Additionally, it can identify patients at
greater risk of transformation with lesions that may otherwise be considered low risk on
microscopic examination.
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5.2.4 S100A7 manual score analysis: 3-tier, 2-tier and Straticyte™
One of the specific aims of this study was to examine the utility of the different assays
used to assess the dysplasia. As part of determining the utility, correlation between
S100A7 manual scoring, and the 3-tier or 2-tier grading system was assessed. A Pearson
correlation coefficient was calculated to identify a statistically significant relationship
involving all populations and another was calculated for each of the individual test
populations (tables 4.21, 4.22, 4.23). The expectation prior to carrying out the staining
was that severe or high-grade dysplasia would have greater staining. When considering
all populations, our study found weak correlation between S100A7 manual scoring and
both the 3-tier and 2-tier grading systems. When the populations were evaluated with
Pearson correlation individually, the relationship was negligible with only the
Progressing group having a weak relationship with the 3-tier system. None of these
relationships were statistically significant which makes it difficult to draw conclusions.
One source of discrepancy could lie in the analysis of the whole epithelium as compared
to specific ROIs. The grade of dysplasia will be determined by the worst area, which can
be very focal on microscopic examination. As such, the diagnosis can potentially be
made based on a very small percentage of the overall epithelium present. When the
S100A7 manual score was calculated, the whole epithelium was assessed, therefore a
very focal area of strong staining would not result in a maximum score, despite a
potential focal severe or high grade dysplasia.
Interestingly, when the Pearson correlation was applied to Straticyte™, and the
relationships with the 3-tier and 2-tier grading systems were assessed, the correlational
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relationships were very similar to the S100A7 manual scores with the 3-tier and 2-tier
grading systems, with negligible to weak correlation existing, which was not statistically
significant (tables 4.21, 4.22, 4.23). Again, drawing meaningful conclusions is difficult.
This is not what was originally expected, given that both Straticyte™ and the 3-tier and
2-tier grading systems rely on specific ROIs to determine the diagnosis. The diagnosis of
hyperkeratosis in the Control group is interpreted as a constant in the Pearson correlation,
therefore it cannot be assessed individually. The stronger relationships between all
populations and the individual populations is likely due to the inclusion of the Control
group in the total population calculation (table 4.21 and 4.24).
The Pearson correlation coefficient indicates statistically significant moderate and strong
relationships between S100A7 manual scoring and Straticyte™ for all populations (tables
4.21, 4.22, 4.23, 4.24). This is interesting given the discussion above regarding ROIs as
compared to whole epithelial assessment, however it is feasible given the theory of field
cancerization. Despite the tissue in the surrounding regions appearing
histomorphologically normal, intracellular and molecular changes in keeping with the
process of malignant transformation could be present well beyond the more obviously
dysplastic tissue (168). This is a potential benefit with these tests as the staining occurs
at a molecular level, and therefore may identify tissue that appears relatively normal
histomorphologically. Based on the validation study of Straticyte™, which demonstrates
the ability of Straticyte™ to identify lesions at increased risk of malignant
transformation, a strong relationship between S100A7 manual scoring and Straticyte™,
could be beneficial in identifying lesions that are at greater risk of malignant
transformation, therefore effecting clinical follow up for the specific patient.
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5.2.5 QuPath assessment of S100A7 staining
Our study also utilized QuPath for assessment of the S100A7 manual scoring in an
attempt to improve objective measurement for tissue scoring (tables 4.19, 4.20, 4.25,
4.26, 4.27, 4.28). By utilizing the software’s annotation tools, the area of staining was
more precisely determined as compared to the more subjective area assessment of the
S100A7 manual score. This has the potential to improve reproducibility which addresses
significant issues with inter-observer and intra-observer variability when assessing and
grading dysplasia. In combination with S100A7 staining, this could be an effective way
for pathologists to further characterize tissue. In addition, the software can be utilized for
more precise cell counts. This was not relevant in our study due to the diffuse nature of
the staining, although the identification of nuclei could improve cell counts and
potentially aid in the differentiation of cytoplasmic and nuclear staining. Nuclear staining
of S100A7 of epithelial cells has been reported in the literature to be associated with
cancer free survival (131). In the study by Tripathi et al, it was demonstrated that the
over-expression of nuclear S100A7 staining was a poor prognostic indicator for not only
cancer free survival but also overall outcomes. If automated identification of nuclear
staining could be achieved and calculated against total nuclei (total cells) within the area
of interest, the utility of QuPath could improve.
In this study, ANOVA, Tukey comparison and Pearson correlation were applied to
QuPath results, the 3-tier and 2-tier grading systems, S100A7 manual scoring and
Straticyte™ for the specific tissue samples used in the QuPath analysis. This showed that
the three populations could not be differentiated using the S100A7 manual score, likely
due to the small sample size, but when QuPath was utilized to assess the tissue staining, a
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statistically significant difference between the Progressing group and the Control group
was identified. When Pearson correlation was applied, the QuPath score had the
strongest correlation with the S100A7 manual score, for all three populations.
5.6 MAPK
MAPK signaling pathway protein immunohistochemical staining of tissue samples in this
study was interpreted to be unsuccessful. While staining was attempted to identify
dysregulation in phosphorylated protein activity, the tissue stained relatively uniformly,
with what appeared to be significant non-specific staining. While staining of activated
phosphorylated proteins is known to be difficult, irregular and unexpected staining may
have resulted due to delayed staining of the prepared slides. In this study, some of the
tissue was cut and prepared months prior to staining, which may have resulted in loss of
specificity for some of the proteins in the pathway due to tissue deterioration.
5.7 Future considerations
Obtaining a biomarker that can sufficiently identify lesions at increased risk of malignant
transformation is of vital importance. The potential impact on clinical management could
be significant. Possible impacts include increased surveillance of patients with an
increased risk of malignant transformation, and decreased clinic visits for those at low
risk. For the patient, the benefit is in personalized care. The current model has patients
return to clinic for evaluation every 3-6 months, although less than half of dysplastic
lesions go on to develop OSCC. In addition, a number of patients with initial diagnoses
of non-dysplastic lesions progress and undergo malignant transformation (3)(102). This
implies that some of the molecular changes that result in malignant transformation are not
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perceptible on initial light microscopy. While the current results indicate S100A7
manual scoring was unable to distinguish between dysplastic lesions that progress to
malignancy from those that do not, there was a statistically significant difference between
those that progressed and the hyperkeratosis group. Therefore, there is potential utility
for S100A7 staining and assessment to determine if these patients are at risk.
This study shows that S100A7 has predictive utility for malignant transformation in
potentially malignant lesions. S100A7 manual scoring is relatively inexpensive and quick
and can be completed within the same laboratory as the initial tissue sample. The
interpretation can be carried out at the same time as other stains during the diagnostic
assessment by the pathologist. In order to further increase specificity, ROIs could be
assessed as opposed to the total epithelium. By limiting the interpretation of the slides to
specific regions of interest, the total area of epithelium assessed would change, which
would alter the percentage score component of the S100A7 manual score. This may
improve the utility of the S100A7 manual score.
Additionally, the location of S100A7 staining within either the nucleus or cytoplasm
could provide value in potentially identifying lesions at risk of malignant transformation.
Nuclear staining is used as part of the Straticyte™ protocol, which demonstrated the
ability to differentiate the Progressing from the Non-progressing groups. With the
integration of staining location with the S100A7 manual score, differentiation of the
populations may improve.
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5.8 Limitations
Further information regarding patient habits both past and present would have improved
this study. Unfortunately, the information regarding tobacco or alcohol status was
incomplete for most as health care professionals submitting the tissue samples for
assessment often failed to provide this information. If complete, this information could be
included in the statistical analysis of the S100A7 manual score, which may improve our
understanding of the S100A7 expression, and further improve its utility. One way of
enhancing the amount of demographic information collected would be to include specific
headings on the referral form. As many clinicians are filling out the information
regarding the specimen during their busy clinics, and may inadvertently only include
minimal information. If prompted, this information is more likely to be provided. The
information will have already been collected during the initial consult.
The lack of a statistical difference in S100A7 scores between the two dysplastic
populations is likely due to the heterogeneity of each of the groups. Heterogeneity in this
case means that despite the identification of seemingly two distinct populations,
progressors and non-progressors, within each group, there may be differences that we are
unable to identify, that ultimately result in different subgroups within the population.
With each subgroup, perhaps different outcomes would be expected if we could identify
them. In particular, the progression to OSCC happens over a period of time which is
variable, unpredictable at this time, and can occur after many years. This is supported by
many studies which indicate that the average time to malignant transformation is three to
five years, with some progressing more rapidly, and others taking several decades to
transform. In addition, the proportion of dysplastic lesions that progress to OSCC is
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greatest within the first two years (106)(169)(3)(85). While we attempted to select cases
from four years previous to account for malignant transformation, some transformation
can be expected to occur beyond four years. Therefore, despite multiple biopsies without
malignant transformation, the Non-progressing population may contain patients who have
yet to undergo malignant transformation but are likely to. As such, the heterogeneity is
in the fact that there really may be two subgroups within the Non-progressing population,
that we are unable to differentiate using our current method of identification; one of
which may still undergo malignant transformation and hence truly belong in the
Progressing group. It is also conceivable that some patients for whom only one biopsy
was found, may have relocated to other parts of the province or country and are no longer
receiving care within the catchment of the UWO pathology service. A second biopsy,
recurrence or transformation may have occurred without our knowledge. In addition,
patients may have died of other causes. In both cases, this would represent sampling bias.
10 patients from the Non-progressing group in our study only had one biopsy, and
potentially may have been affected by sampling bias.
With respect to QuPath, a major disadvantage was that the use of the software was time
consuming. The main reason for this is that staining of the epithelium and the underlying
connective tissue was difficult for the automated annotation tool to differentiate. An
over-estimate of the epithelium, with inclusion of the underlying connective tissue was
commonly encountered, therefore, the user was still required to manipulate the annotation
tool to outline the epithelium accurately. Given the moderate and strong correlation
between the QuPath score and the S100A7 manual score, the practical value of the
QuPath evaluation may be limited because of the time commitment for each of the tissue
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samples, as Pathologists may be more inclined to assess the S100A7 staining directly
using the light microscope rather than by using image analysis software. Further
assessment of the S100A7 staining with QuPath utilizing ROIs would be beneficial in
determining the if the software provides greater value than S100A7 manual scoring
alone.
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CHAPTER 6: CONCLUSION
6.1 Conclusion
The primary goal of our study was to demonstrate that elevated S100A7 expression in
tissue samples correlates with increased risk of malignant transformation. In addition, we
looked to evaluate the utility of the 2- and 3-tier grading systems, S100A7 manual
scoring and the S100A7 assay Straticyte™ in identifying dysplastic lesions at increased
risk of malignant transformation. A subset of patient tissue samples were also evaluated
with QuPath, an open source software for evaluation of histopathological specimens.
This was done to assess potential utility of the software for improved assessment and
scoring of tissue samples.
Each of the modalities was utilized to assess three populations: a Control population
comprised of patients with hyperkeratosis, without dysplasia or malignant transformation,
a Non-progressing population, with dysplasia which has not become malignant, and a
Progressing population. This population demonstrates malignant transformation at a site
of a previous lesion or dysplasia.
We attempted to differentiate the three study populations by assessing the proportion and
intensity scoring of S100A7 expression within the oral mucosa. Our study showed that
with S100A7 immunohistochemical staining, we were able to differentiate dysplastic
tissue specimens from the non-dysplastic specimens of the Control group, giving valueadded information for the pathologist to consider when grading dysplastic epithelia. This
may be beneficial in cases of uncertainty between inflamed tissue or dysplasia. Given this
utility, there is still promise, for differentiation of progressing from non-progressing
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dysplasia. Perhaps more specific criteria are required to further hone the specificity of the
S100A7 assay by including location of staining and evaluating specific regions of interest
as opposed to the whole epithelium itself, as demonstrated by the Straticyte™ risk score,
which was able to differentiate Progressing dysplasia from Non-progressing dysplasia
groups. Utilizing QuPath as a means of evaluating the S100A7 offers potential for
improving reproducibility for the S100A7 manual score and provides interesting
prospective for further testing of its utility in these cases, as this study demonstrated
promising preliminary results.
The current study demonstrates that the strongest correlation exists between S100A7
manual scoring and the Straticyte™ risk score. This correlation existed when applied to
the Progressing and Non-progressing populations, and provides valuable information
regarding both methods S100A7 staining evaluation.
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